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ABSTRACT OF THE DISSERTATION
Modulation of Human and Malarial Glucose Transporter Activity by Lipids and Small Molecules
by
Thomas E. Kraft
Doctor of Philosophy in Biology and Biomedical Sciences
Biochemistry
Washington University in St. Louis, 2016
Professor Paul W. Hruz, Chair
Professor Colin G. Nichols, Co-Chair
Glucose transport is a fundamentally important process for maintenance and regulation of
cellular metabolism in all kingdoms of life. Despite their high importance, detailed examination
of glucose transport proteins in humans and parasites through biochemical, biophysical and
structural properties was greatly hampered by the inability to express, purify and reconstitute
sufficient amounts of active transporters. This dissertation describes strategies that led to the
first successful expression, purification, stabilization and functional reconstitution of active
insulin-responsive GLUT4 transport protein. Furthermore, the work described herein
establishes a requirement of anionic and conical lipids for full activity of the mammalian
glucose transporters GLUT3 and GLUT4, thereby extending the field of known membrane
protein-lipid interactions to the family of structurally and functionally related human solute
carriers. Because of its crucial role in parasite survival, the malarial glucose transporter PfHT has
been extensively validated as drug target for different parasitic life stages in vitro and in animal
models. The emergence of parasites with resistance to even the most potent existing antimalarial drugs has made paramount the development of novel drugs that target essential

xi

pathways for parasite survival. We identified PfHT as molecular target of the antimalarial
activity of the clinically used HIV inhibitor lopinavir which had been shown previously to
decrease parasite viability in vitro, in vivo, and in patients. In order to find novel PfHT inhibitors
with increased potency and selectivity over human orthologs, a high-throughput assay was
developed that uses fluorescence as direct readout of PfHT mediated glucose transport
inhibition. Validation of this approach was demonstrated by our success in identifying several
verified hits in a screen of the MMV malaria box compound library. Importantly, we identified a
potent PfHT inhibitor with >10 fold higher selectivity for PfHT over its human orthologs. These
findings have high potential for direct application in large-scale screens and new drug
development. Taken together, this work provides a novel framework for ongoing efforts to
directly

target

glucose

transporters

in

xii

the

treatment

of

human

disease.

Chapter 1 - Introduction

1.1 Sugars are used to store, transport and provide energy in all forms of life
Sugars provide energy and building blocks to all living cells. Light energy is converted into
chemical energy by plants and algae through photosynthesis through conversion of carbon
dioxide and water into mainly sugars which are consumed by all forms of life ranging from
bacteria to fungi to multicellular organisms. In higher organisms, sugars are synthesized
through gluconeogenesis. Therefore, sugars can be regarded as the predominant energetic
currency and source of carbon for all non-photosynthetic forms of life. Sugar transport is an
essential step in cellular metabolism. Carrier proteins mediate the regulated movement of
hydrophilic sugar molecules over the hydrophobic cell membrane barrier. Most sugar
transporters show high specificity for mono- and disaccharides and mediate transport either
through facilitated diffusion or through proton or sodium coupled cotransport1. Facilitative
sugar carriers of uniporters transport their substrate along a concentration gradient thereby
equilibrating the intra- and extracellular concentration. Electrochemical gradients of counterions allow cotransporters or secondary active transporters to move substrates against
concentration gradients. This process is particular important in concentrating sugar inside
specific cells as observed in the reabsorption of glucose from glomerular filtrate to the blood by
kidney cells2 or in the accumulation of nutrients by bacteria3.
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1.2 Sugar transporters are part of the major facilitator superfamily
The major facilitator superfamily (MFS) encompasses structurally and functionally related
facilitative and secondary active sugar transporters that share a common fold comprising 12
transmembrane helices with intracellular amino- and carboxy-termini. These sugar carriers are
evolutionary conserved and can be found in different forms of life ranging from mono- and
disaccharide transporters in plants4,5, monosaccharide transporters like the recently crystallized
proteins GlcP and XylE6,7, the large family of hexose transporters in yeast 8, glucose transporters
in the infectious stages of several parasites 9 or the Glucose Transport protein (GLUT) family of
membrane transporters expressed in various tissues and cells of mammals10. Bacterial sugar
transporters have been characterized in great detail using mutational and functional analysis of
their substrate specificity, key residues for transport and substrate binding, and transport
mechanism11. The most prominent example is the bacterial lactose permease LacY. Its
architecture and conformational transitions have been closely examined using various
structural techniques including X-ray crystallography12, electron paramagnetic resonance
double electron-electron resonance (EPR DEER) and molecular dynamics (MD) simulations.
Prior to the structure determination of human GLUTs, much of the knowledge about MFS fold
transporters was derived from this model protein; however, bacterial and mammalian sugar
transporters differ in several important aspects. Most bacterial MFS sugar transporters function
as proton coupled symporters7,13–16 while all mammalian GLUTs with the exception of HMIT are
uniporters. Additionally, they share less than 35% sequence identity7,13,17, which complicates
extrapolation from bacterial to mammalian transporters. Finally, the lipid bilayer in which these
transporters are embedded in, playing an important role in regulating their activity, differs
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significantly in composition and bilayer thickness between bacteria and mammals 18–20.
Therefore, it is crucial to directly study the mammalian orthologues in order to understand their
function in human health and disease. The work described in this dissertation focuses on the
mammalian glucose transporters GLUT3 and GLUT4 (Chapters 2 and 3) and the hexose
transporter of the parasite, causing malaria in humans, Plasmodium falciparum, PfHT (Chapters
4 and 5).

1.3 The human GLUT glucose transporters
GLUT proteins facilitate the selective diffusion of hexose and pentose sugars down a
concentration gradient in and out of cells. However, some GLUTs also transport other
substrates including ascorbic acid, urea, glucosamine or myoinositol and for several GLUTs the
physiological substrate is currently unknown 10,21. The 14 GLUTs can be divided into three
classes based on sequence similarity. GLUT3 and GLUT4 belong to class 1 of the GLUT family,
together with GLUT1, GLUT2 and GLUT14. Class two is comprised of GLUTs 5, 7, 9 and 11
whereas GLUTs 6, 8, 10, 12 and HMIT belong to class 3. Class three can be further subdivided
based on comparative genomic analyses22. GLUTs are fundamentally important to human
metabolism as they provide a pathway for regulated cellular influx and efflux of glucose. Every
human cell expresses at least one but most often a combination of several GLUT isoforms10. The
reason for the abundance of these transporter isoforms is most likely the importance of sugar
as an energy source and the need of specialized cells for transporters with specific substrate
affinities, transport capacity or regulation 10. The importance of these transporters becomes
apparent by examining human diseases which are caused or aggravated by impaired GLUT
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function. Class 1 transporters of have been studied in great detail and several related diseases
have been identified. Several dozen mutations of the gene encoding GLUT1 (SLC2A1) cause mild
to severe developmental and metabolic perturbations in individuals diagnosed with GLUT1
deficiency syndrome23. Gene defects in the SLC2A2 gene, affecting the function of GLUT2 result
in hepatomegaly and impaired renal function, known as Fanconi-Bickel syndrome10. Finally,
although not directly caused by mutations in the transporter, impaired GLUT4 function is the
main reason for diabetes related pathology. The pathogenesis of type 2 diabetes relates to the
inability of cells to respond to insulin signaling by initiating GLUT4 translocation to the cell
surface.
GLUTs are encoded by the SLC2A gene family which is part of the superfamily of solute carriers
(SLCs). The SLC family consists of over 400 members that are responsible for nutrient uptake,
drug transport and waste removal24. Although, a quarter of these transporters are associated
with disease in humans, they are relatively understudied24 with crystal structures of only three
members available, all belonging to the GLUT family25–27. SLCs are only half as often the focus of
publications compared to the average over all protein families while showing by far the most
uneven distribution of papers over the group members of all gene families24. This discrepancy
can be explained by the fact that only few members were primarily studied due to their
abundance in easily isolated cell types, which greatly facilitated their examination in the time
before molecular biology techniques were readily available, as well as the difficulty of purifying
milligram quantities of most active mammalian membrane proteins, a requirement for their
biochemical and structural characterization. However, in recent years, technological advances
and the development of new methodologies laid the groundwork for research aiming to close
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this gap. In this dissertation, I describe the first purification of active GLUT4 transporter protein
and its biochemical characterization in various lipid mimetics using several state of the art
techniques to express, purify and stabilize mammalian membrane proteins (Chapter 2). GLUT4
is mainly expressed in skeletal muscle and adipose tissue. It is responsible for depositing
glucose into skeletal muscle, thereby maintaining serum glucose concentrations28. Its activity is
tightly regulated through the translocation between intracellular storage vesicles and the cell
surface. Upon binding of the hormone insulin, an intracellular signaling cascade is activated that
leads to the fusion of GLUT4 containing vesicles with the plasma membrane (PM)28. In Chapter
3, I describe an additional mechanism for modulation of GLUT4 activity. We determined that
glucose transporters GLUT3 and GLUT4 require the presence of anionic phospholipids in the PM
for activity and that conical lipids increase the activity of these transporters up to 6-fold in the
presence of anionic lipids. This study is the first comprehensive analysis of the effect of lipids on
the activity of two member of the mammalian SLC family and provides a model for the
mechanism of lipid activation. By providing novel insights into the function of this class of
membrane proteins, we have laid the ground work for pharmacological manipulation of their
activity.

1.4 Inhibition of glucose transporter function
Transporter function is commonly manipulated using small molecules that bind the protein with
high affinity and inhibit its function. Cancer metabolism and sugar uptake through human
GLUTs are promising targets for cancer therapy as specific GLUT isoforms are highly expressed
in certain cancer types. Cancer cells consume increased amounts of glucose which is used as
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the predominant source of energy through high rates of glycolysis followed by lactic acid
fermentation (Warburg effect)29–31. GLUT1 in particular has been targeted in preclinical studies
for its high abundance in many cancer cells32,33. Beyond cancer, sugars are an important energy
source in all cellular organisms. Therefore, glucose transport is an essential process that can be
exploited for pharmacological targeting also in pathogens like protozoan parasites. Previous
studies demonstrated that glucose transport is essential for the viability of infectious stages of
Trypanosoma brucei34–37, Leishmania mexicana38,39, and P. falciparum40. Indeed, compounds
that inhibit the glucose transporters of T. brucei41 and P. falciparum40 have been identified. The
malarial glucose transporter PfHT has been extensively validated as drug target and the glucose
analogue, compound 3361, has been found to inhibit viability of the parasite in different life
stages in vitro and in animal models42,43. In the intraerythrocytic stage of infection, glucose is
transported from blood into the erythrocyte via the abundantly expressed transporter GLUT1
where it passes freely into the parasitophorous vacuole before reaching the parasite surface.
Finally, glucose uptake into the parasite is mediated through PfHT44. We identified PfHT as an
antimalarial target of the HIV protease inhibitor lopinavir (Chapter 3) which had been shown
previously to decrease parasite viability in vitro, in vivo, and in patients45–50. However, its
mechanism of action remained unknown. Additionally, we developed a high throughput
screening assay directed at identifying PfHT inhibitors with high selectivity over its human
orthologues (Chapter 4). The assay has several advantages over conventional uptake assays
employing radiolabeled substrates. It uses fluorescence as a direct readout of glucose uptake
inhibition and can be easily adapted for other glucose transport proteins.

6

In summary, the work described in this dissertation helps to better understand the basic
mechanism of mammalian glucose transport and provides a novel way to pharmacologically
target transporters that play important roles in human diseases.
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Chapter 2 – Expression, Purification, and Functional Characterization of the
Insulin-Responsive Facilitative Glucose Transporter GLUT4

Thomas E. Kraft1, Richard C. Hresko1, Paul W. Hruz1,2,†

1

Department of Pediatrics, and 2Department of Cell Biology and Physiology, Washington

University School of Medicine, St Louis MO 63110
†

corresponding author
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2.1 Abstract
The insulin-responsive facilitative glucose transporter GLUT4 is of fundamental importance for
maintenance of glucose homeostasis. Despite intensive effort, the ability to express and purify
sufficient quantities of structurally and functionally intact protein for biophysical analysis has
previously been exceedingly difficult. We report here the development of novel methods to
express, purify and functionally reconstitute GLUT4 into detergent micelles and
proteoliposomes. Rat GLUT4 containing FLAG and His tags at the amino and carboxy termini,
respectively, was engineered and stably transfected into HEK-293 cells. Over-expression in
suspension culture yielded over 1.5 mg of protein per liter of culture. Systematic screening of
detergent solubilized GLUT4-GFP fusion protein via fluorescent-detection size exclusion
chromatography identified lauryl maltose neopentyl glycol (LMNG) as highly effective for
isolating monomeric GLUT4 micelles. Preservation of structural integrity and ligand binding was
demonstrated via quenching of tryptophan fluorescence and competition of ATB-BMPA
photolabeling by cytochalasin B. GLUT4 was reconstituted into lipid nanodiscs and proper
folding was confirmed. Reconstitution of purified GLUT4 with amphipol A8-35 stabilized the
transporter at elevated temperatures for extended periods of time. Functional activity of
purified GLUT4 was confirmed by reconstitution of LMNG-purified GLUT4 into proteoliposomes
and measurement of saturable uptake of D-glucose over L-glucose. Taken together, these data
validate the development of an efficient means to generate milligram quantities of stable and
functionally intact GLUT4 that is suitable for a wide array of biochemical and biophysical
analyses.
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2.2 Introduction
The regulated glucose transport across biological membranes is of fundamental importance to
maintenance of glucose homeostasis. Defects in this process contribute to several human
diseases including diabetes mellitus28. Mammalian glucose transport is mediated by a family of
membrane glycoproteins (GLUTs) that serve as passive uniporters, facilitating glucose
permeation down a concentration gradient by alternating access to its glucose binding site via a
proposed rocker-switch mechanism51. The GLUTs are members of the sugar porter subfamily of
the major facilitator superfamily (MFS), one of the largest and most ubiquitous secondary
transporter superfamilies52,53. Both the amino and carboxy termini are located on the
intracellular side together with a large loop connecting helices six and seven (Fig. 2.1). GLUT1
(SLC2A1) is the most extensively characterized of the GLUTs, largely due to the abundance of
expression of this protein in the erythrocyte membrane. Initially cloned by Mueckler et al in
198554, GLUT1 has been studied by a variety of traditional biochemical techniques including
cysteine-scanning mutagenesis55,56. The insulin-responsive transporter GLUT4 (SLC2A4) is highly
expressed in skeletal and cardiac muscle, brown and white adipose tissue and mediates the
rate limiting step in regulated transport in these tissues. Although GLUT4 thus plays a key role
in controlling whole body glucose homeostasis, the structure of this protein remains poorly
characterized. This has been due in part to the inherent difficulties in isolating GLUT4 with
retention of functional activity.
Purification of this transporter is the prerequisite for all structural and dynamic studies like Xray crystallography, NMR, EPR or single molecule FRET. Additionally, experiments studying the
effect of different membrane lipids on GLUT4 function are difficult without reliable purification
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and reconstitution of active protein. Most of these approaches require hundreds of microgram
to milligram quantities of this protein. Additionally, reconstituting the protein into membrane
mimetics like detergent micelles, amphipols, nanodiscs and liposomes that stabilize the protein
for several days in its properly folded, active conformation is crucial for subsequent biochemical
and structural experiments. In spite of the availability of various expression systems and
purification techniques, mammalian membrane proteins continue to pose a considerable
challenge for large scale, functional purification due to their instability once isolated from their
native lipid environment. Another major hurdle for the purification of mammalian membrane
proteins is successful solubilization by detergents. The choice of detergent is critical as it needs
to be harsh enough to solubilize the protein from its native lipid environment but mild enough
to stabilize its three-dimensional structure and preserve activity. Here we report the first
successful large scale expression, purification, stability optimization and functional
reconstitution of the mammalian insulin responsive glucose transporter GLUT4.
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2.3 Results and Discussion
Expression
We tested several expression systems in our laboratory including E.coli, S. cerevisiae and insect
SF9 cells for over-expression of GLUT4 with only limited success. Difficulties encountered in
these systems have included poor transporter expression, protein misfolding with generation of
inclusion bodies, and production of GLUT4 lacking detectable glucose transport activity.
Although GLUT4 has previously been expressed in P. pastoris, presence of protein in a
monomeric state and functional activity could not be demonstrated 57. Prokaryotes lack posttranslational modifications and differ in the membrane lipid composition from eukaryotes, two
important characteristics that often determine the successful use of a heterologous expression
system58. In general, these hosts either do not express sufficient quantities or yield poorly
folded protein. We utilized the mammalian cell line HEK293 to expresses over 1.5 mg of
functional GLUT4 per liter of culture. Using a modification of the protocol previously reported
by the Stroud lab59, we created a stably GLUT4 expressing, tetracycline inducible HEK293S GnTI cell lines. After selecting the highest expressing cell line from 10 individual clones, expression
was verified by western blot analysis (Fig. 2.2A). Functional activity of the expressed transporter
was tested by comparing radiolabeled 3H-2-deoxy-glucose (3H-2DG) uptake into tetracycline
induced and uninduced cells as well as untrasfected control HEK293 GnTI- cells (Fig. 2.2B).
Induced cells overexpressing GLUT4 showed a more than two-fold increase in glucose uptake
over background (uninduced and untransfected). This uptake could be completely inhibited by
the GLUT specific inhibitor cytochalasin B (CB). We further analyzed intracellular protein
localization by expressing GLUT4 tagged with AcGFP at the protein carboxy-terminus. In
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addition to the plasma membrane, large amounts of the protein were found in intracellular
vesicles, resembling the native state of the protein 28. The transporter is known to undergo
significant post-translational processing60,61. GLUT4 expression levels were monitored over time
using western blot analysis of whole cell lysates which peaked at 72h post induction
(Supplementary figure 2.1). The HEK293S GnTI- clone showing the highest GLUT4 expression
was grown up in adherent culture and transferred to suspension culture. Cells in suspension
culture were grown at 1-4x106 cells/ml in square bottles on an orbital shaker and harvested 72h
post induction with tetracycline.
Detergent screening
It is imperative to find a detergent that solubilizes GLUT4 efficiently from its lipid environment
while maintaining native three-dimensional fold and function. Currently, large libraries of
detergents have to be screened to empirically identify suitable candidates as there is no way to
predicting a priori the best detergent for a newly purified membrane protein. We used
fluorescent-detection size exclusion chromatography (FSEC) to rapidly detect oligo-or
monomeric state, stability and overall homogeneity to rank different detergents for
downstream purification and biochemical studies of the protein. HEK293S GnTI - cells,
transiently expressing AcGFP, linked to GLUT4’s C-terminus were harvested, homogenized and
split into several aliquots. Each aliquot containing whole cell homogenate was treated with 1%
detergent and subjected to size exclusion chromatography following detection of whole protein
absorption and AcGFP fluorescence. Large void volume peaks are indicative of detergents
leading to protein aggregation and misfolding. Shape and peak area of the monomer peak are
excellent indicators of protein quality. Detergents with high solubilization efficiency that
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stabilize a homogeneous population of GLUT4 will result in monodisperse, symmetric peaks
whereas detergents that lead to multiple conformations or aggregated states will result in
polydisperse, asymmetric peaks, often at higher stokes diameter. We screened 29 detergents
from different classes using the FSEC method and identified LMNG and the fos-choline 13-16
family as suitable detergents for the detection of monomeric, symmetric peaks with minimal
void peaks (Fig. 2.3A-C). We further tested GLUT4 stability in commonly used detergents like
DDM, DM and Triton X-100. DDM had previously been identified as the detergent of choice for
purifying GLUT457. We found LMNG to be superior compared to the other tested detergents in
stabilizing GLUT4 over several days (Fig. 2.4). This stability is crucial for successful protein
crystallization trials, which require maintenance of homogenous protein for several days to
weeks to facilitate crystal formation. Detergents that lead to heterogeneous protein
populations will have a low likelihood of yielding highly diffracting crystals. LMNG belongs to a
novel class of detergents that have shown great potential in solubilizing and stabilizing
membrane proteins compared to conventional detergents 62,63. In order to further increase
stability of GLUT4 in detergent we screened several additives that were previously reported to
stabilize membrane proteins. Non-detergent sulfobetaines in particular have been shown to
prevent protein aggregation and help protein folding 64,65. Glycerol is also well known for its
stabilizing effect on both soluble and membrane proteins66,67. Additionally, we tested several
compounds that are known to bind to the transporter and possibly lock it into a single
conformational state68,69. Cytochalasin B is a tightly binding glucose transport inhibitor, locking
GLUT4 into its inward facing conformation69, thus stabilizing it. We found that glycerol has a
similar beneficial effect on transporter stability while allowing free movement between
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different conformations (Supplementary Fig. 2.2). These results correlate with the findings of
Boulter et al. on GLUT1 stability70. We have observed that using glycerol in all purification and
subsequent characterization steps allows for increased flexibility in temperature and analysis
time.
Purification
We tested several purification strategies with various tags on GLUT4. The protein is largely
tolerant of modification at both the N- and C-terminus as well as the extracellular loop between
helix 1 and 271–73. We tested purification using a 9x-His tag, a Strep-tag, a Twin-Strep-tag and a
FLAG tag at both the N- and C-termini. All experiments described in this manuscript were
conducted using the FLAG and His-tagged constructed depicted in Fig. 2.1. Use of anti-FLAG
affinity gel produced highly concentrated, nearly homogenous protein that could be further
purified to greater than 95% purity in a single size exclusion chromatography (SEC) step
(Fig. 2.5A, B). Due to the high affinity of the resin to the FLAG tag, more than 90% of the GLUT4
in whole-cell lysate were bound after a three hour incubation time. In contrast, having tested
various Strep-Tactin resins and optimized conditions for binding of the strep-tag II and twinstrep tagged GLUT4 also in combination with prior IMAC purification, we found only 5-10% of
total GLUT4 in whole cell lysate to be bound which is a loss of 90-95% of protein. However, the
eluted protein showed high purity. We conclude that because FLAG affinity gel has an over 300
times higher affinity for the FLAG tag compared to Strep-Tactin for the strep-tag II74,75, it is
therefore better suited to purify proteins of low abundance like membrane proteins expressed
in mammalian culture systems.
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Using the immobilized metal-affinity chromatography (IMAC) with His-tagged GLUT4 more than
60% of the tagged protein was bound but even stringent washing steps or binding in the
presence of imidazole led to an elution product insufficient purity for further isolation using
SEC. Mammalian cells have a high natural abundance of proteins containing consecutive
histidine residues that often lead to contaminations in IMAC purifications 76. Additionally, the
IMAC system is often not suitable for purifications of proteins with low abundance that require
greater than 100-fold enrichment77 as we experienced in the case of GLUT4 expressed in
HEK293S cells.
The only disadvantage to using anti-FLAG affinity gel compared to the other tested methods is
the greatly increased cost, especially as the affinity of the gel decreased significantly after one
use in whole cell lysate. Purification using anti-FLAG affinity resin and one SEC step routinely
yields 600-700μg of >95% pure protein per liter of cell culture with recovery of ~50% of
expressed protein after all purification steps. Both N- and C-terminal tags could be cleaved
completely within three hours using TEV protease.
Testing correct protein folding by ligand binding
To verify that GLUT4 was correctly folded after purification and to test the ability of the
detergents identified in the FSEC screen to maintain functional activity, we first determined the
binding of known GLUT4 inhibitors by fluorescence quenching and a competition binding assay.
All class 1 (GLUT1-4) and class 3 (GLUT6, 8, 10, 12) share two conserved tryptophan residues
(W404 and W428) located within the glucose permeation path that are involved in binding of
inhibitors like CB and conferring substrate specificity78. Cytochalasin B binds to and locks GLUT4
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in its inward facing conformation 79. To explore the binding site of CB we created a model of
GLUT4 in the inward open conformation based on the crystal structure of GLUT1 and docked CB
to it. In this model CB binds to GLUT4 in direct contact of the two tryptophan residues and
possibly quenches their fluorescence by changing the polarity of their environment (Fig. 2.6A,
B). Binding of CB has been shown to quench the fluorescence of these residues in GLUT1, both
in intact membranes and in detergent indicating proper folding of the transporter as all twelve
helices have come together in the correct geometry to create the CB binding site within the
glucose permeation path70,80. In Figure 2.6D, we show for the first time that GLUT4 tryptophan
fluorescence is quenched by CB with a dissociation constant K ds of 1.4 μM. The emission
maximum at 345nm shifts to a lower wavelength and its intensity is reduced by roughly 20%
(Fig. 2.6C). These observations are in agreement with CB quenching for purified GLUT1 70 and
indicate correct folding of the LMNG purified GLUT4. Additionally, we determined ligand
binding and competition of GLUT4 in LMNG by testing the binding of the photolabel ATB-BMPA
and the ability of CB to compete for ATB-BMPA binding81. ATB-BMPA contains the glucose
analogue bis-mannose and is known to bind at the glucose binding site of class 1 transporters 68
(Fig 2.7A). ATB-BMPA binds to folded GLUT4 in LMNG in comparison to heat denatured GLUT4
(Fig 2.7B) and the amount of CB competition is comparable to GLUT4 in native lipid
membranes82.
We also measured tryptophan quenching of GLUT4 purified in Fos-Choline 14 (FC14). The SEC
peak of purified GLUT4 in FC14 shifts towards a higher molecular weight, indicating
dimerization, aggregation or partial misfolding of the protein (Supplementary Fig. 2.3A).
Titration of CB confirmed this observation as tryptophan fluorescence could not be quenched
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for GLUT4 in FC14 micelles compared to LMNG (Supplementary Fig. 2.2B). Since in contrast to
the observed effect of CB on GLUT4 in LMNG micelles the transporter in FC14 micelles does not
appear to bind this ligand, we conclude that the protein is most likely misfolded in this
detergent environment.
Increased stability in different membrane mimetics
Various molecules like detergents, amphipols, nanodiscs or liposomes have been identified to
mimic the lipid bilayer environment surrounding a membrane protein in the cell. Each mimetic
exhibits specific advantageous properties: Detergents envelop membrane proteins in micelles
and are generally inexpensive, available with various chemical modifications like deuteration
and are the number one mimetic for crystallization studies83. Amphipols do not form micelles
but wrap around the hydrophobic core of the membrane protein thereby stabilizing it while
eliminating problems like phase separation or viscosity increase due to a lack of free polymer in
solution84. Nanodiscs are formed by a scaffold protein belt that envelopes a lipid bilayer disc in
which a membrane protein is inserted. A major advantage of nanodiscs is their similarity to the
cellular lipid bilayer. This can allow investigation of the membrane protein in a near native
environment with determination of direct effects of lipids on protein structure, function and
dynamics. The ability to modulate nanodisc size by varying the scaffold protein used provides a
platform for many different applications including nuclear magnetic resonance (NMR), electron
paramagnetic resonance (EPR), surface plasmon resonance (SPR) or single molecule FRET
(smFRET). An important feature of nanodiscs is that simultaneous access is provided to both
sides of the membrane surface. While facilitating investigation of protein and small molecule
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interactions, this system does not allow for the direct measurement of transport activity.
Liposomes are the closest to a native environment for membrane proteins, allowing lateral
diffusion and generating curvature. The most important application for liposomes are
functional studies as they generate an outside and an inside compartment for the membrane
protein, allowing uptake studies for transporters and channels. Several recent reviews have
presented additional details on the relative strengths and limitations of different membrane
mimetics85,86. We developed reconstitution protocols for GLUT4 in these membrane mimetics
to increase stability and allow studying of this transporter using various techniques. The SEC
profile of GLUT4 has been a good indicator of stability and aggregation and correlates with the
ability of the protein to bind inhibitors and take up glucose. Reconstituting GLUT4 in the
amphipol A8-35 greatly increased the protein stability at elevated temperature (Fig. 2.8A) and
increased the possible NMR acquisition time at 35°C from 2 to 36 hours without detecting
protein aggregation by comparing peak intensity and chemical shifts over time. A8-35 was even
able to refold GLUT4 after high pH-induced partial unfolding (Fig. 2.8B). To test correct protein
folding and function we tested CB binding by tryptophan fluorescence quenching and
confirmed a similar Kds as already shown for GLUT4 and GLUT1 in detergent (Fig. 2.8C).
Nanodiscs can be used to study the influence of lipid composition on the structure and
dynamics of GLUT4 by NMR, EPR and smFRET. To demonstrate that GLUT4 could be successfully
reconstituted into nanodiscs, we tested two different detergents to solubilize the lipid for the
nanodisc assembly step and compared GLUT4 binding to known ligands as described in Fig. 2.7A
using ATB-BMPA. Reconstitution using either cholate of Triton X-100 yielded monomeric SEC
peaks (Fig. 2.9A). GLUT4-nanodiscs reconstituted using Triton X-100 bound approximately 70%
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of ATB-BMPA per total GLUT4 compared to cholate, indicating a higher percentage of correctly
folded transporter in cholate reconstituted nanodiscs (Fig. 2.9B).
To truly measure GLUT4 function, the purified transporter needs to be reconstituted into a lipid
membrane that separates two distinct compartments allowing quantification of glucose
transport. We reconstituted LMNG purified GLUT4 into liposomes and measured zero-trans
specific uptake of radiolabeled 3H-D- and nonspecific 3H-L-glucose (Fig. 2.10). We conclude that
purified GLUT4 is functional and shows characteristic saturable uptake of D-glucose over Lglucose in liposomes. Beyond proving function of purified GLUT4, this assay allows us to
determine the effect of individual lipid properties like chain length, charge and headgroup on
GLUT4 function and correlate that data with disease phenotypes where an altered lipid
composition is observed.

2.4 Conclusion
Major technical advances including the growing availability of novel detergents, improved cell
expression systems, the development of artificial membrane mimetics more closely resembling
native lipid environments, and expanding knowledge of the utility of small molecules to
stabilize protein conformation have greatly contributed to the successful isolation and
biophysical characterization of mammalian membrane transporters. Building upon this
foundation, we have developed a highly robust and reliable system to generate sufficient
quantities of homogenous functionally intact GLUT4 for biophysical analysis and have provided
a framework for future characterization of the structure and dynamics of this protein. Thus, the
most significant roadblock to the determination of membrane protein structure has been
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largely overcome for GLUT4. With this success in hand, an accelerated pace of discovery both in
elucidation of the structural and dynamic underpinning of glucose transport and the
development of innovative means to manipulate transporter activity are now on the immediate
horizon.

2.5 Materials and Methods
Cell Culture
DMEM and calcium-free DMEM were purchased from US Biological (Salem, MA). Adherent
HEK293 cells were grown in DMEM at 5% CO2 in a humidified incubator and split before they
reached confluency. Suspension culture HEK293S GntI - cells were grown in 2 liter square bottles
on orbital shakers (220rpm) in custom made DMEM medium according to 59 with the addition of
60 mg/l dextran sulfate (Mr 5000). Cells were grown at a density of 0.5-4.5*106 cells/ml and
spun and resuspended into fresh media every 3 days. Stable cell lines expressing GLUT4 under a
tet-on-promotor were induced 72h before harvest according to59. Cells were spun and
resuspended at 2-3*106 cells/ml in fresh medium with the addition of 3g/l Primatone RL
(Sigma-Aldrich), 2g/l D-glucose (Sigma-Aldrich), 5mM sodium butyrate and 2mg/l doxycycline
hyclate (Sigma-Aldrich).
Molecular Biology
Purification tags and protease cleavage sites were introduced via PCR according to 87 using
Phusion Hot Start II High-Fidelity DNA Polymerase from Fisher Scientific. We used GLUT4 from
R. norvegicus as template and added a FLAG tag (DYKDDDDK) followed by a triple glycine linker
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and a TEV protease site (ENLYFQS) followed by a triple glycine linker to the N’-terminus as well
as a triple glycine linker followed by a TEV protease site, a triple glycine linker and a deca
histidine tag to the C-terminus. This construct was placed within the multiple cloning site of the
pACMV-tetO vector88 using SalI and NotI restriction enzymes to create the pACMV-tetO-FT-G4TH plasmid. To create a GLUT4-AcGFP fusion protein, we attached the AcGFP gene (Clontech) to
the carboxy-terminus of GLUT4, separated by a triple glycine linker in the pACMV-tetO plasmid
via PCR according to87.
Generation of stable cell lines
Stable cell lines were generated according to 59. HEK293 GnTI- cells (ATCC® CRL-3022) were
stably transfected, first with the SapI linearized pcDNA6/TR vector (life Technologies) to create
a tetracycline inducible cell line, then with the SmaI linearized plasmid pACMV-tetO-FT-G4-TH
using the Optifect Transfection Reagent (life Technologies) according to the manufacturer’s
instructions. Cells that stably incorporated the plasmid into their genome were selected using 5
μg/ml blasticidin (pcDNA6/TR) and 2 mg/ml geneticin (pACMV-tetO-FT-G4-TH). Ten single
colonies were isolated using cloning cylinders (Sigma Aldrich CLS31668) and expanded to 6-well
plates. 72 hours after induction with 2 μg/ml doxycycline, cells were harvested, lysed and
solubilized using 1% (v/v) Triton X-100. Highest expressing clones were identified using western
blot analysis of cell lysate against polyclonal GLUT4 antibody (custom produced by Invitrogen
using a peptide corresponding to the 16 carboxyl-terminal residues of GLUT4).
2-DOG uptake into HEK293 cells
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Uptake of [3H]-2DOG into HEK293 cells was measured in HEPES buffered saline solution at room
temperature for 4 min as described previously68. Cells were previously glucose starved for 30
min at room temperature in HEPES buffered saline solution.
Detergent and additive screening
We screened several detergent families (Anatrace) and the additives glycerol (Sigma Aldrich),
cytochalasin B (Enzo Life Sciences), D-glucose (Sigma Aldrich), indinavir sulfate (Fisher) and
NDSB-256 (VWR) using the fluorescent size exclusion method according to Kawate and
Gouaux89. HEK293 GnTI- cells were transiently transfected using pACMV-tetO-FT-GLUT4-GFP
plasmid using the Optifect Transfection Reagent (life Technologies) according to the
manufacturer’s instructions. Cells were lysed in PBS buffer with 30 strokes of a dounce
homogenizer, split into multiple aliquots and solubilized for 1.5h at 4°C by addition of various
detergents to 1% (w/v). After ultracentrifugation, the supernatant was injected on a Superdex
200 10/300 GL column (GE Lifesciences) with buffer A (50 mM potassium phosphate, 150 mM
NaCl, 0.1% (w/v) DDM, pH 7.4) and GLUT4-AcGFP fluorescence was detected using a Waters
474 scanning fluorescence detector (Ex = 475nm, Em = 505nm).
Purification
Frozen cell pellets were thawed in a 30°C water bath and resuspended in buffer B (50 mM
potassium phosphate, 150 mM NaCl, 15 % (vol/vol) glycerol, 3 mM EDTA, protease inhibitor
(Sigma Aldrich), 1 μg/ml DNAse I (Roche) and 1mM PMSF (Fisher)). Cells were broken by passing
them through a microfluidizer at 13,000 psi four times. Membrane proteins were solubilized by
addition of 0.75% (w/v) LMNG (Anatrace) and rotated at 4°C for 1h. Cell lysate was spun at
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75,000 x g for 45min at 4°C and the supernatant was filtered through a 0.45 μm filter to remove
insoluble matter. The filtered supernatant was incubated with washed M2 anti-FLAG affinity gel
(Sigma Aldrich) according to the manufacturer’s instructions for 3h with rotation. GLUT4 bound
FLAG affinity gel was collected in a column and subjected to extensive washing with 30 column
volumes of buffer C (50 mM potassium phosphate, 150 mM NaCl, 15 % (vol/vol) glycerol, 3 mM
EDTA, complete protease inhibitor (Roche), 0.1% (w/v) LMNG, pH 7.0. GLUT4 protein was
eluted with six subsequent additions of 0.5 column volumes elution buffer (buffer C containing
200 μg/ml FLAG peptide, 100 μg/ml 3x FLAG peptide (ApexBio)). Protein containing fractions
were pooled and tags were cleaved with TEV protease (plasmid purchased from Addgene) at a
ratio of 1:20 TEV:GLUT4 over night at 4°C in the presence of 1mM DTT. The cleaved protein was
concentrated using a VIVASPIN 6 PES 10000 MWCO concentrator (Sartorius Stedim) and
purified via size exclusion chromatography (SEC) using a Superdex 200 10/300 GL column (GE
Lifesciences) with buffer D (50 mM potassium phosphate, 150 mM NaCl, 0.1% (w/v) LMNG, pH
7.0). Purity was assessed via SDS gel electrophoresis with IRDye Blue protein staining (LI-COR).
Modeling and docking
GLUT4 structure was predicted using the I-TASSER webserver90–92. We chose a model that
resembled the inward open conformation based on the crystal structure on the close
homologue GLUT113. Docking was performed using AutoDock Vina93. The receptor was
prepared using MGLTools version 1.5.6 and the ligand CB was prepared using ArgusLab. The
docking process was completed with number of modes of 50 and exhaustiveness of 50. The
results in each attempt were 20 similar docked poses. Docked poses were displayed using
PyMOL version 1.7.4.0.
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Fluorescence quenching
Cytochalasin B binding to GLUT4 was measured by tryptophan quenching according to70. SEC
purified protein was equilibrated in a 50μl quartz fluorometer cell (Starna Cells, 16.50F) for
10min at 25°C in a Cary Eclipse Fluorescence Spectrophotometer (Varian) with circulating water
bath. CB was added from a stock solution in DMSO.
Ligand binding assay
Binding of the biotinylated bis-mannose compound ATB-BMPA in the presence and absence of
20μM CB was determined according to68. After photolabeling, GLUT4 was repurified using M2
anti FLAG antibody (Sigma Aldrich) and analyzed by western blot using fluorescently labeled
streptavidin (IRDye 800CW, LI-COR).
Reconstitution into membrane mimetics
Amphipol- GLUT4 was eluted in elution buffer at pH 8.0 to stabilize the amphipol. After the
addition of A8-35 amphipol (Anatrace) at a ratio of 1:4 (w/w) GLUT4:amphipol the protein was
rotated for 15 minutes at room temperature. After addition of Amberlite XAD-2 (Sigma Aldrich)
in excess to remove detergent and TEV protease as described before we incubated the protein
on a rotator at 4°C overnight. GLUT4 in amphipol was separated from Amberlite beads using a
column and purified by SEC with buffer E (50 mM potassium phosphate, 150 mM NaCl, pH 8.0).
Nanodiscs- GLUT4 nanodiscs were assembled according to Sligar and coworkers94. Briefly, lipids
dissolved in chloroform (Avanti Polar Lipids) were dried down (EggPC:POPE:POPA 70:15:15
molar ratio) and resuspended in buffer C containing either 100mM sodium cholate or 100mM
triton X-100 to a final lipid concentration of 50mM. The sample was purged with argon and
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vortexed/sonicated until the solution was clear. Lipid, MSP1E3D1 scaffold protein and purified
GLUT4 in LMNG were combined at a molar ratio of 130:1:0.1 and rotated for 30 min at 4°C.
Detergents were removed by the overnight addition of Amberlite XAD-2. After removal of
Amberlite XAD-2, GLUT4 containing nanodiscs were separated from empty discs by purification
using M2 anti-FLAG affinity gel and SEC as described above.
Liposomes-GLUT4 containing liposomes were assembled according to Knol et al.95. Briefly, lipids
were mixed in chloroform (EggPC:POPE:POPS 70:15:15 molar ratio), dried down under nitrogen
and residual chloroform was removed under vacuum for 4h. The dried lipid film was
resuspended in buffer C with rigorous vortexing followed by five freeze/thaw cycles in liquid
nitrogen and room temperature. The lipids emulsion was extruded eleven times through 200
nm polycarbonate filters (Whatman) to form large unilamellar vesicles. Triton X-100
destabilized liposomes were incubated with purified GLUT4 for 45 min 4°C followed by
detergent removal using Amberlite XAD-2 beads. After removal of all beads, liposomes were
collected by ultracentrifugation at 4°C for 1 h at 267,000 x g and resuspended in buffer
containing 50 mM potassium phosphate (pH 7.4) and 130 mM KCl. Samples could be stored
after this step at -80°C after flash freezing in liquid nitrogen. Glucose uptake assay
Liposome 3H-2DG uptake
Frozen liposomes containing purified GLUT4 were thawed at room temperature and subjected
to three freeze/thaw cycles (liquid nitrogen/room temperature) followed by extrusion through
a 200 nm polycarbonate filter. Uptake was started by adding 3H-D-glucose (200 μM) (American
Radiolabeled Chemicals) to GLUT4 proteoliposomes. Transport was stopped at different times
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with ice-cold phosphate buffer containing 100 μM phloretin and then filtered by vacuum on a
0.2 μm mixed cellulose ester filters (Avantec). Scintillation fluid was added to the filters and the
radioactivity counted. 3H-L-glucose (200 μM) was used to determine nonspecific transport.
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2.8 Figures

Figure 2.1. Predicted topology map of GLUT4. The membrane topology was predicted using the
TOPCONS web server for consensus prediction of membrane protein topology and signal
peptides96. Grey amino acids were added for aiding purification and removal of purification
tags.
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Figure 2.2. Functional expression of GLUT4 in HEK293 GnTI- cells determined by western blot
and glucose uptake. Expression of FLAG and 10xHis tagged GLUT4 was determined using
western blot analysis via anti GLUT4 antibody (A). Function of the protein was assessed by
measuring zero-trans influx and accumulation of 3H-2-Deoxy-glucose in cells before and after
induction of GLUT4 expression by doxycycline (B). Uptake in the presence of vehicle (EtOH) was
compared to the GLUT specific inhibitor cytochalasin B (CB). Glucose uptake in the absence of
doxycycline can be attributed to basal glucose uptake for energy homeostasis as indicated by
similar levels of uptake in untransfected control cells. Data is expressed as mean ±SEM
(***P<0.001; one-way ANOVA analysis).
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Figure 2.3. FSEC elution profiles of detergent solubilized GLUT4-AcGFP. Several detergents
were used to solubilize HEK293 cells containing AcGFP tagged GLUT4. Peak shape, size and
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Figure 2.4. Stability of GLUT4 in various detergents over time determined by FSEC. GLUT4AcGFP was solubilized in DDM, DM, LMNG and Triton X-100 and incubated at 4°C for 68 hours.
Aliquots were analyzed by FSEC after 0h, 20h, 44h and 68h. The flow rate was 0.55 ml/min.
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Figure 2.5. Purity assessment of FLAG and SEC purified GLUT4 by SEC and SDS-PAGE. FTGLUT4-TH in LMNG micelles was analyzed for purity after purification via anti FLAG affinity gel
and size exclusion chromatography (SEC) by SEC (A) and by IRDye Blue protein staining of
polyacrylamide gel after SDS-PAGE (B). GLUT4 elutes as a sharp, single, symmetric peak from
the SEC column. The flow rate was 0.55 ml/min.
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Figure 2.6. CB binding to GLUT4 analyzed by tryptophan fluorescence quenching. CB (pink)
binds within the glucose permeation path formed by the N-terminal (blue) and C-terminal half
(green) of the transporter in the inward facing conformation in all docked poses (A).
Representative pose of CB shows binding in direct proximity of two tryptophan residues lining
the glucose permeation path that were previously identified to be the target of fluorescence
quenching by CB70,97,98 (B). Fluorescence intensity was scanned between 310-390nm with
excitation at 295nm for increasing concentrations of CB (C). Fractional change of fluorescence
was plotted against CB concentrations (D) and Kds was calculated using non-linear regression
analysis (GraphPad 6.0). Data is expressed as mean ±SEM.
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Figure 2.7. Assessment of binding of the glucose analogue ATB-BMPA in the presence and
absence of the inhibitor CB. Biotinylated ATB-BMPA contains the glucose analogue bismannose and is known to bind at the glucose binding site of GLUT4. GLUT4 in LMNG micelles
was photo-labeled with ATB-BMPA and analyzed by western blot using fluorescently labeled
streptavidin (A). Vehicle treated transporter labeling was compared to CB treated and negative
controls including no photolabeling (no UV) and heat denatured GLUT4 (B).
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Figure 2.8. Stabilizing effect of amphipol A8-35 on GLUT4 determined by SEC and fluorescence
quenching. (A) Reconstitution of GLUT4 into amphipol preserves the structure of the protein as
assayed by SEC before (dark blue) and after (light blue) incubation at 40°C for 2 hours
compared to LMNG after incubation at 40°C for 2 hours (red). (B) Amphipol was able to refold
GLUT4 (blue) after partial, basic pH induced (pH 10) induced misfolding in LMNG (orange). (C)
GLUT4 reconstituted in amphipol is binding the known inhibitor CB as assayed by tryptophan
fluorescence quenching. Kds was calculated using non-linear regression analysis (GraphPad 6.0).
Data is expressed as mean ±SEM.
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Figure 2.9. SEC elution profiles of GLUT4 reconstituted into nanodiscs and CB inhibitable
binding of ATB-BMPA. GLUT4 reconstituted into MSP1E3D1 nanodiscs using sodium cholate
(red) or triton X-100 (blue) for lipid solubilization elutes as a single, symmetrical peak from the
size exclusion column indicating homogeneity of the protein population (A). GLUT4 in cholate
and triton X-100 assembled nanodiscs shows reduced binding of ATB-BMPA in the presence of
the competitive inhibitor CB. The ratio of Strep/GLUT4 indicates the fraction of GLUT4 labeled
with ATB-BMPA. The flow rate was 0.55 ml/min.
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Figure 2.10. GLUT4 mediated uptake of 3H-D- and 3H-L-glucose into liposomes. Saturable,
specific zero-trans uptake of 3H-D-glucose into GLUT4 reconstituted liposomes (red) compared
to nonspecific uptake of 3H-L-glucose (blue). Uptake data was fitted using non-linear regression
analysis (GraphPad 6.0). Data is expressed as mean ±SEM.
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Supplementary Figure 2.1. Expression levels of GLUT4 over time post induction. HEK293 GnTIcells stably expressing GLUT4 under a tet-on promoter were induced in triplicate with
doxycycline and sodium butyrate. Cells were harvested at different time points, lysed and
subjected to western blot analysis using a GLUT4 antibody (A). The intensities of the band at
around 45kDa was quantified to determine the expression levels of GLUT4 at different time
points (B).
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Supplementary Figure 2.2. Stabilizing effect of different additives on GLUT4 in LMNG
determined by FSEC. LMNG solubilized GLUT4-AcGFP cell lysates were incubated at 37°C
overnight in the presence or absence of 0.5M D-glucose, 20% (v/v) glycerol, 20μM CB, 200μM
indinavir and 0.5M NDSB-256. The flow rate was 0.55 ml/min.
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Supplementary Figure 2.3. Testing correct three-dimensional folding of GLUT4 purified in
FC14 micelles. SEC elution profiles show a shift to larger stokes diameter from LMNG
solubilized GLUT4 (red) to FC14 solubilized GLUT4 (blue) (A). Increasing concentration of CB
does not significantly affect tryptophan fluorescence intensity of GLUT4 in FC14 (B), indicating
no specific CB binding to GLUT4. Both results indicate misfolding or aggregation of the
transporter.
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3.1 Abstract
The regulated movement of glucose across mammalian cell membranes is mediated by
facilitative glucose transporters (GLUTs) embedded in lipid bilayers. Despite the known
importance of lipids in regulating protein structure and activity, lipid-induced effects on the
GLUTs remain poorly understood. We systematically examined the effects of biologically
relevant phospholipids on glucose transport in liposomes containing purified GLUT4 and GLUT3.
For both GLUTs, anionic phospholipids were found to be essential for functional activity.
Phosphatidic acid, phosphatidylserine, phosphatidylglycine or phosphatidylinositol significantly
increased transport activity in a dose-dependent manner. Although not essential, the conical
lipids phosphatidylethanolamine and diacylglycerol enhanced transporter activity up to
threefold in the presence of anionic phospholipids. Kinetic analyses revealed that anionic and
conical lipids increase the kcat of transport without changing the Km. These results extend the
field of known membrane protein-lipid interactions to the family of structurally and functionally
related human solute carriers.
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3.2 Introduction
Membrane proteins are embedded in a lipid bilayer that covers a large percentage of their
exposed surface. Lipid bilayers in typical human cells consist of hundreds of different lipid types
that modulate cell signaling and protein function 99. Membrane lipid composition changes in
several disease states and varies markedly over different cellular compartments. This influences
the activity of transmembrane proteins by direct interactions with specific lipids or through
changes in the biophysical properties of the membrane (e.g. fluidity, permeability, curvature,
charge density and lateral pressure)20,100. Each membrane protein interacts with several lipid
molecules at any given time, yet understanding the functional and structural effects of these
contacts has been previously limited. With the advent of several methodological advances in
isolating and studying membrane proteins, the significance of individual lipid components has
begun to emerge. Human and bacterial ion channels, aquaporin Z, LacY and the nicotinic
acetylcholine receptor are among the growing list of membrane proteins that have been shown
to require specific lipids like anionic phospholipids, phosphatidylethanolamine (PE), cholesterol
or signaling lipids like phosphatidylinositol bisphosphate (PIP 2) for optimal activity or proper
folding101–108.
The solute carriers (SLCs) consist of over 400 family members in humans. A quarter of these are
associated with disease, making them excellent targets for clinical research 24. Although highly
important in nutrient uptake, drug transport and waste removal, this class of proteins remains
relatively understudied24. Elucidation of the lipid requirement for activity of mammalian solute
carriers remains of paramount interest for drug discovery and general understanding of
transport mechanisms.
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Members of the SLC2A family of facilitative hexose transporters are essential in regulating
cellular metabolism by selectively transporting glucose down a concentration gradient without
the use of energy. To date, 14 distinct human SLC2A isoforms (GLUTs) have been identified109
and for several of these proteins the cellular function in health and disease has been
established.

Regulation of the insulin-responsive facilitative glucose transporter GLUT4

(SLC2A4), which is primarily responsible for mediating peripheral glucose disposal in insulin
sensitive tissues such as skeletal and cardiac muscle as well as adipose tissue 110, has been
intensively studied in relation to the pathophysiology of type 2 diabetes mellitus 111. Under basal
conditions, the majority of GLUT4 remains sequestered within the cytosol in specialized
membrane vesicles. Upon stimulation by insulin, a complex signaling cascade is initiated which
results in the translocation of GLUT4 to the cell surface112. In contrast, GLUT3 (SLC2A3), which
has been classically defined as the neuronal glucose transporter due to the high level of
expression and initial characterization in nervous tissue113, is constitutively present on the cell
plasma membrane. GLUT3 is also highly expressed in other tissues with high energy needs
including sperm, embryonic tissue and leukocytes114. Despite the longstanding recognition of an
association between changes in membrane lipid composition and glucose transport in human
disease115,116, the role of specific phospholipids on the functional activity of individual GLUT
isoforms remains elusive. Although initial studies on the influence of lipids on the activity of
GLUT1 isolated from erythrocyte membranes were performed nearly 30 years ago117, until
recently it was not possible to isolate and reconstitute other GLUT isoforms in a functional form
to allow comprehensive evaluation of membrane lipids, alone or in combination, at
physiologically relevant levels.
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Here, for the first time we demonstrate that the glucose transport activity of GLUT4 and GLUT3
is controlled by the membrane phospholipid composition. Based on biochemical data and on
crystal structures of GLUT3 and the close homologues GLUT1 and GLUT5 in multiple
conformations, the currently accepted mechanism of action for these transporters is defined by
interconversions between inward- and outward- facing conformations via a rocker-switch
motion, governing the transport of solutes over the membrane barrier 25–27. Our findings expand
the current model by introducing the modulation of transporter activity by specific
phospholipids, thereby highlighting the importance of two classes of phospholipids that might
regulate the activity of other members of the SLC family.

3.3 Results
GLUT4 and GLUT3 show specific and saturable uptake of glucose in liposomes of defined
phospholipid composition.
To study the effect of different phospholipids at specific concentrations on the activity of
GLUT4 and GLUT3, we developed an assay system allowing us to measure uptake of
radiolabeled glucose into liposomes that contained purified transporter embedded in a tightly
controlled lipid environment. Both transporters showed saturable uptake over seconds to
minutes of their primary substrate D-glucose over the non-transportable L-glucose in liposomes
containing 70% egg phosphatidylcholine (eggPC), 15% phosphatidic acid (PA) and 15% PE
(mol/mol) (Supplementary Results, Supplementary Fig. 3.1). Transport could be completely
abolished using the GLUT-specific inhibitor cytochalasin B (Supplementary Fig. 3.1a). As
expected for random insertion, the transporter incorporated into liposomes with roughly half in
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an outward- and half in an inward- facing orientation. Evidence for this conclusion was obtained
from western blot analysis of the transporter using anti-FLAG antibody before and after
tobacco etch virus (TEV) protease cleavage of an engineered N-terminal FLAG tag. In detergent
micelles, the protease has access to both faces of the transporter whereas in liposomes, it can
only access transporters that orient with their N-terminus facing outward. We determined
cleavage of the FLAG tag of 100% in micelles, whereas only 50% of all transporters in
liposomes are cleaved by TEV protease.
Anionic phospholipids stabilize GLUT4 and are required for activity of GLUT4 and GLUT3.
We hypothesized that similar to several ion channels and receptor proteins, mammalian
transporter function is regulated by its lipid environment. Several studies have shown that
specific binding of annular lipids to various membrane proteins stabilize their structure and
modulate their function118–120. For example Laganowsky et al. demonstrated the stabilizing
effect of lipids directly binding to several membrane proteins by preventing gas-phase
unfolding in ion-mobility mass spectrometry experiments at increasing voltage 119. Similar to this
approach, we devised a simple method to efficiently identify lipids that stabilize the
transporter. Microgram amounts of LMNG detergent purified monomeric GLUT4 were
incubated in the presence or absence of various lipids followed by thermal destabilization. The
ability of specific lipids to stabilize the folded protein was assessed via SEC. We previously
established that a single, symmetrical peak in the SEC elusion profile corresponds to
monomeric, properly folded, active GLUT4 whereas multiple, asymmetric peaks that elute
earlier are an indicator of a heterogeneous population of destabilized, unfolded or aggregated
protein121. In the presence of anionic phospholipids, a monomeric peak of folded GLUT4,
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comparable to unheated, folded GLUT4 in LMNG micelles, was retained on the SEC profile
(Fig. 3.1a) whereas zwitterionic and non-bilayer phospholipids did not stabilize the transporter,
similar to heated GLUT4 in LMNG micelles (Fig. 3.1b).
The observation that only anionic phospholipids stabilize the transporter structure prompts the
question as to whether these lipids also modulate the function of GLUT4. We assessed the
activity of the transporter in liposomes containing 100% eggPC or eggPC liposomes containing a
second lipid at an 85:15, molar ratio. No specific GLUT4 mediated uptake was observed in the
zwitterionic phospholipids PC, PE, or sphingomyelin (SM) (Fig. 3.2a). In contrast, the addition of
the anionic phospholipids, PA or phosphatidylserine (PS) activated the transporter and resulted
in specific D-glucose uptake (Fig. 3.2b). These results indicate a requirement for anionic
phospholipids for transport activity and confirm our SEC results. To study the effect of the
major naturally occurring anionic phospholipids in eukaryotic membranes in detail, we titrated
palmitoyl-oleoyl-phosphatidic

acid

(POPA),

palmitoyl-oleoyl-phosphatidylserine

(POPS),

palmitoyl-oleoyl-phosphatidylglycerol (POPG) and phosphatidylinositol (PI) into PC liposomes
and measured GLUT4- mediated uptake of D-glucose (Fig. 3.2c). All four anionic phospholipids
led to a dose-dependent activation of GLUT4 with PA exhibiting the strongest effect, PS the
second, followed by PI and PG. Anionic phospholipids also activated GLUT3 but with important
differences (Fig. 2d). Unlike GLUT4, GLUT3 possessed measurable, albeit low transport activity
in the absence of anionic phospholipids. The addition of anionic phospholipids greatly
enhanced GLUT3 activity, with PS having the most potent effect, followed by PA, then PG and
PI. These results demonstrate that anionic phospholipids are required for optimal GLUT4 and

47

GLUT3 activity and suggest the presence of an anionic phospholipid binding site on the
transporter with different affinities for anionic phospholipid headgroups.
Conical lipids stimulate glucose uptake in liposomes that contain anionic phospholipid.
Nonbilayer lipids like palmitoyl-oleoyl-phosphatidylethanolamine (POPE) have been shown to
increase the activity of several membrane proteins in the presence of anionic
phospholipids103,122–124. To assess the effects of POPE on GLUT4 activity, we measured glucose
transport in liposomes containing 10 % POPA in eggPC, titrated with increasing amount of
POPE. POPE significantly increased glucose uptake reaching a maximum effect of three-fold at
30% POPE (Fig. 3.3a). We next determined the effect of anionic phospholipids on GLUT4 activity
in the presence of POPE. Glucose transport measured in liposomes containing 30% POPE in
eggPC were titrated with POPA. As expected, POPA stimulated glucose uptake in a
concentration-dependent manner and no specific uptake was observed in 30% POPE in the
absence of anionic phospholipid (Fig. 3.3b). Unlike the other predominant mammalian
zwitterionic lipids PC or SM, POPE is conically shaped with a small headgroup and one
unsaturated acyl chain that occupies a larger volume than saturated chains. To determine
whether the activating effect of POPE on GLUT4 is mediated through specific binding of the
lipid to the transporter, as suggested for anionic phospholipids, or through altering the
biophysical properties of the lipid bilayer, we compared the effect of the non-bilayer lipid
palmitoyl-oleoyl-glycerol (DAG) to POPE. Both lipids share the same aliphatic tails but
significantly differ in their headgroup with DAG completely lacking the phosphate group and
therefore exhibiting an even stronger conical shape than POPE (Fig. 3.3c). In the presence of
DAG, GLUT4 activity was increased in a dose-dependent manner, similar to POPE (Fig. 3.3d).
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DAG showed a more pronounced effect on transporter activity with a maximal activation of 2.5fold higher than POPE, correlating with its stronger conical shape. Although it is unlikely that
DAG has a physiological role in activating GLUT4 as the amount in the PM is a small fraction of
PE125, this experiment demonstrates the activation of GLUT4 through a headgroup unspecific
effect on the biophysical properties of the lipid bilayer. This effect was also observed for GLUT3
(Fig. 3.3e). The addition of 15% conical lipids (POPE) increased transporter activity by 2.7-fold in
the presence of anionic phospholipids. Similar to GLUT4, conical lipids did not significantly
increase transporter activity of GLUT3 in the absence of anionic phospholipids. These results
establish that conical lipids are necessary but not sufficient for optimal GLUT4 and GLUT3
transport activity.
Anionic and conical lipid increase transporter activity in liposomes with physiological lipid
composition.
Like DAG, the levels of PA in mammalian PMs are quite low (~1%) and therefore the more
abundant anionic phospholipids PS and PI most likely contribute more significantly in terms of
enhancing normal glucose transport activity. To determine whether the anionic and conical
lipid effects are also observed in a more physiological environment, GLUT4 activity was
measured in liposomes with a phospholipid composition comparable to that of a mammalian
PM

125

(Fig 3.4a). Cell plasma membranes show trans-bilayer lipid asymmetry with anionic

phospholipids being found exclusively and conical lipids preferentially on the cytoplasmic face
(inner leaflet), a feature that distinguishes eukaryotic from prokaryotic membranes 99. Due to
the technical challenge of generating asymmetric vesicles that recapitulate native mammalian
cell membranes, characterization of the major phospholipids was carried out in liposomes
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comprised of lipid levels found in either the PM inner leaflet (Fig. 3.4b) or the total PM
membrane (Fig. 3.4c). To assess the contribution of each individual phospholipid on glucose
transport, we determined transporter activity in liposomes after subsequent additions of lipids
to the previous mix, starting with eggPC. From left to right each bar represents an experiment
in which an additional lipid was added to the previous lipid mix thereby reducing the molar
amount of eggPC. The precise lipid compositions for each experiment can be found in
Supplementary Tables 3.1 and 3.2. As expected, in the presence of only the zwitterionic,
cylindrical lipid eggPC no specific uptake was detected while the addition of the anionic
phospholipid PS significantly increased D-glucose uptake above background. Uptake was
dramatically enhanced upon the further addition of the conical lipid PE. Adding the other
zwitterionic lipid SM to the system had no effect on glucose uptake while the addition of
physiological levels of PI further increased uptake. PA addition had no measurable effect on
transport suggesting that either the lipid binding sites on GLUT4 are already saturated by the
other anionic phospholipids PS or PI or that the levels of PA in the PM are indeed too low to
have any contribution. As anticipated, liposomes resembling the inner leaflet lead to increased
GLUT4 activity due to the higher concentrations of anionic and conical lipids compared to
liposomes comprised of lipid compositions that approximate total PM.
Anionic and conical lipids increase the maximal activity of GLUT4 and GLUT3 but not their
substrate binding affinity.
We used kinetic analysis to determine the mechanism of lipid-induced changes of glucose
transporter function. By measuring zero-trans uptake of radiolabeled D-glucose into transporter
containing liposomes at increasing substrate concentrations with different amounts of anionic
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or conical lipids present, we determined the Michaelis constant K M and the turnover number
kcat. For both GLUT3 and GLUT4, increasing concentrations of anionic or conical lipid increased
the turnover number linearly but had no measurable effect on the Michaelis constant (Fig. 5).
These data support a mechanism in which anionic and conical lipids increase the fraction of
active transporters and/or the transporter interconversion rate without changing substrate
binding affinity. Therefore, at saturating substrate concentration, anionic and conical lipids alter
the rate-determining step in facilitative glucose transport. Similar to previous studies 126, the
reconstituted transporter GLUT3 showed higher affinity for D-glucose than GLUT4 while it
transported its substrate with a lower turnover number than GLUT4. The K M for GLUT3 (11.9 ±
1.6 mM) and GLUT4 (33.3 ± 5.1 mM) reconstituted in liposomes was higher than reported
when expressed in cells, which is consistent with previously published studies comparing
transporter kinetics in cells versus reconstituted into liposomes 127–131. Measuring transporter
kinetics of GLUT4 expressed in HEK293 cells prior to purification and reconstitution, we
observed a lower KM of 7.1 ± 1.1 mM (Supplementary Fig. 3.3), similar to previously published
studies126,132. These results indicate that additional cellular components, not present in the
purified four-component liposome system, might play a role in altering the transporter’s K M.
The slope of the transporter kcat plotted against the concentration of anionic or conical lipids
correlated with the intensity of the lipid effect on transporter activity and allows direct
comparison of isoform-selective lipid effects. For both the anionic phospholipid PA and the
conical lipid PE, the kinetic data show a 5-fold higher slope for GLUT4 compared to GLUT3,
indicating a significantly stronger dependence of GLUT4 on anionic and conical lipids for
activity. As expected, extrapolation to 0% PA indicated a negligible turnover number for GLUT4
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where very little specific transport was observed. However, GLUT3 retained minimal activity
even in the absence of anionic phospholipids. This correlates with our earlier data in which
transport activity was measured in liposomes containing only PC or PC plus PE (Fig. 3.3e).

3.4 Discussion
Taken together, our data demonstrate that anionic and conical lipids are essential for full
activity of the mammalian glucose transporters GLUT4 and GLUT3 but activate the transporters
through distinct mechanisms. In this first in-depth, systematic study of the lipid dependences of
any mammalian solute carrier protein, a key finding is that anionic phospholipids are required
for activity and mediate this effect through their headgroups (Fig. 3.2c). All activating anionic
phospholipids tested share the same fatty acids and a negative charge on the phosphate group
but differ in the headgroup substituents (Fig. 3.2e). The zwitterionic lipids that were examined
also share the same fatty acid moieties but carry a positive charge on their headgroup
substituent that neutralizes the negatively charged phosphate group, and do not activate the
transporters (Fig. 3.2a). The anionic phospholipid POPA shows potent activation of the
transporters but carries no headgroup substituent, suggesting that the negatively charged
phosphate group mediates the activating effect as the only common denominator. Hinging on
the fact that anionic phospholipids are found exclusively on the inner leaflet of mammalian
PMs, we propose that the interaction partner of the negative charge on the lipid is a cationic
residue on the cytoplasmic face of the transporters, forming an anionic phospholipid binding
site (Fig. 3.6a), similar to inward rectifier channels 104. The stabilizing effect of anionic
phospholipids on GLUT4 protein (Fig. 3.1) provides supporting evidence for a direct interaction
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of annular anionic phospholipids with the transporter in contrast to an effect mediated through
changes of the lipid bilayer chemical properties by bulk lipids. Additionally, the differences in
GLUT4 and GLUT3 activation through anionic phospholipids with chemically different
headgroup substituents is most likely caused by a difference in binding affinities of the lipids to
the anionic phospholipid binding site on the proteins (Fig. 3.2c,d).
Conversely, conical or non-bilayer lipids alone are not sufficient for GLUT4 or significant GLUT3
activity but increase transporter activity dramatically in the presence of anionic phospholipids
(Fig. 3.3a,e). Interestingly, this effect is not mediated through the headgroup, charge or acyl
chains but through their conical shape. The shape of a lipid is determined by the ratio of
headgroup to tail cross sectional area. Conical lipids have large tails, often carrying single or
multiple double bonds and small headgroups while cylindrical lipids have tails and headgroups
of similar size. The conical lipid POPE and the cylindrical lipid palmitoyl-oleoyl-phosphatidyl
choline (POPC), the main constitutent of eggPC, share the same tail and charge and only differ
in the methylation of the ethanolamine headgroup substituent (Fig. 3.2e). POPE is primarily
found on the inner leaflet of mammalian PMs, affecting its biophysical properties by
introducing lipid packing defects, curvature frustration and lowering the lateral pressure at the
aqueous-lipid interface. POPE increased transporter activity in a dose dependent manner in the
presence of anionic phospholipid, while POPC showed no effect (Fig. 3.3a,e). Interestingly, at
physiological concentrations of anionic and conical lipids (Fig. 3.4a), we observed maximal
activity of GLUT4 in liposomes containing 10% POPA and 30% POPE (Fig. 3.3a). Even more
strikingly, the DAG lipid tested, which shares the same acyl chains as POPE but completely lacks
the phosphate headgroup, making it even more conically shaped than POPE (Fig. 3.3c) showed
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a nearly three-fold greater activation of GLUT4 compared to POPE (Fig. 3.3d). Similarly,
nonbilayer lipids stimulate the activity of several other integral membrane proteins in the
presence of anionic phospholipids103,122,124.
In summary, our results show that anionic and conical lipids influence the activity of GLUT4 and
GLUT3 in different ways: Anionic phospholipids are required and sufficient for activity while
conical lipids alone are not sufficient but increase activity significantly in the presence of anionic
phospholipids. Additionally, the presence of anionic phospholipids increases the stability of
GLUT4 as determined by SEC whereas conical lipids have no influence on protein stability,
indicating direct binding of only anionic phospholipids to the transporter. Moreover, our kinetic
analysis of both transporters revealed that anionic and conical lipids increase the kcat linearly in
a concentration dependent manner while the KM remains unchanged. This suggests that both
lipids do not change the affinity of the transporters for their substrate D-glucose but change
either the turnover number of the transporters or the fraction of active transporters. Therefore,
we propose the following model of lipid activation: According to recently published crystal
structures of the GLUT isoforms GLUT1, GLUT3 and GLUT5 in inward and outward facing
conformations25–27, we assume that the transport of glucose is controlled by alternating
between inward and outward facing conformations via a rocker-switch motion and by a gatedpore mechanism involving transmembrane helices 7 and 10. Alternation between inward and
outward facing conformations is catalyzed by the equilibrium of formation and breaking of
transient salt bridges at the cytoplasmic side of the transporter between the ends of several
inter transmembrane helices as well as between intracellular and transmembrane helices 25.
Formation of these salt bridges stabilizes the outward conformation by decreasing total free

54

energy. We propose that anionic phospholipids present cationic residues involved in salt bridge
formation with an alternative binding partner, thereby lowering the energy barrier between
inward and outward conformations (Fig. 3.6c). Salt-bridge forming cationic amino acids would
switch between intramolecular Coulomb interactions with cationic amino acids and
intermolecular interactions with anionic phospholipid headgroups. In the absence of anionic
phospholipids, the transporter would be essentially trapped in an inward or outward state, with
a drastically reduced interconversion rate due to the absence of an alternative binding partner
for cationic amino acids when breaking intramolecular salt bridges (Fig. 3.6a). Increasing
amounts of anionic phospholipid lead to a greater occupancy of the anionic phospholipid
binding site on the transport proteins allowing for the interconversion between both
conformations. The positive correlation between concentration of anionic phospholipids and
transporter turnover number (Fig. 3.5a,b) is therefore a result of an increased fraction of active
transporters. Interestingly, a similar mechanism has been proposed in a recent MD simulation
study of the β2 adrenergic receptor in lipid bilayers133. In the active state, the phosphate group
of an anionic phospholipid forms a salt bridge with an arginine residue, allowing the binding of
the G-protein. Receptor deactivation occurs upon a conformational change that breaks the
lipid-arginine salt bridge and leads to the formation of an intramolecular interaction between
the arginine and a glutamate residue instead.
In contrast, conical lipids in the bilayer introduce lipid packing defects, decrease the interfacial
lateral pressure and create curvature frustration (Fig. 3.6b) thereby leading to increased
flexibility and movement of integral membrane proteins 99,100,134. Consequently, in the absence
of conical lipids, the glucose transporters are embedded into a bilayer of mainly cylindrical
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lipids that provide tight packaging and create strong lateral pressure at the lipid-water
interface, thus stabilizing the transporters’ low energy conformations (Fig. 3.6c). In our model,
we propose that the increase in membrane flexibility by conical lipids in combination with
anionic phospholipid binding leads to a destabilization of the inward and outward open low
energy states (Fig. 3.6c), thereby causing an accelerated rate of interconversion (Fig. 3.6a)
consistent with a conical lipid concentration dependent increase of kcat (Fig. 3.5c,d).
Although further work is required to determine the differences and similarities between GLUT4
and GLUT3 in detail, our findings establish that both transporters require anionic and conical
lipids for full activity. Similar to the previously findings by Tefft et al. for GLUT1 in liposomes
comprised of 100% anionic phospholipid135, we determined that GLUT4 and GLUT3 show a
strong headgroup preference among anionic phospholipids. Importantly, the observed effects
of anionic phospholipid on GLUT4 and GLUT3 are observed at physiologically relevant lipid
levels. GLUT4 is most active in the presence of PA (Fig. 3.2c) whereas GLUT3 and GLUT1 show
highest activity with PS (Fig. 3.2c)135. In contrast to GLUT4, GLUT3 and GLUT1 showed small but
measurable glucose transport activity in PC liposomes in the absence of anionic phospholipids.
Anionic phospholipid effects on transporter kinetics are consistent for all three transporters,
affecting only the turnover number but not the K M135. The same observation was made for
conical lipids in GLUT3 and GLUT4. The turnover number of GLUT4, however, was affected
more strongly by anionic and conical lipids compared to GLUT3 (Fig. 3.5).
The lipid sensitivity of GLUT4 and GLUT3 may have biological implications. Mammalian lipid
composition

varies

significantly

in

different
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tissues

and

also

between

cellular

compartments20,136–138. Concurrently, both transporters show tissue specific expression
patterns with specialized functions in different cell types. Therefore, anionic and conical lipid
concentrations in specific tissues or cellular compartments may coincide with transporter
expression and their lipid requirements for activity. Furthermore, pathologic changes in lipid
composition could affect transporter function and thereby contribute to disease progression,
making lipid bilayer composition a promising pharmacological target. Considering the wide
family of solute carriers implicated in human disease, GLUT4 and GLUT3 have significant
sequence and structural homology to many transporters in this class. Therefore, it will be highly
important to determine if the herein reported lipid dependence is a general phenomenon for
the entire class of SLCs or specific for certain transporters and what the effect the lipid
activation has in the biological function of specific transport proteins.
With markedly expanded understanding of the biophysical effects of lipids on membrane
proteins, advanced techniques for mammalian membrane protein purification, a growing list of
crystal structures for transport proteins, and emerging methodologies to investigate protein
conformational dynamics, our current findings provide the starting point for exploring the lipid
effects that modulate the structure and function of the entire family of solute carrier proteins.

3.5 Material and Methods
Materials. EggPC, POPE, POPS, POPA, POPG, liver PI, brain SM, and 16:0-18:1 DG (DAG) were
purchased from Avanti Polar Lipids Inc. LMNG and OMNG detergent were obtained from
Anatrace. All other reagents were purchased from Sigma-Aldrich or as otherwise indicated.
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GLUT4 expression and purification. Stable tetracycline inducible HEK293S GnTI-cell lines
expressing GLUT4 tagged at the amino and carboxy termini with FLAG and 9xHis respectively
were generated as described previously121. Protein was purified as described in121. Briefly,
frozen cell pellets were thawed in a 30°C water bath and resuspended in buffer B (50 mM
potassium phosphate, 130 mM KCl, 15 % (vol/vol) glycerol, 3 mM EDTA, protease inhibitor, 1
μg/ml DNAse I (Roche) and 1mM PMSF (Fisher), pH 7.4) containing 0.75 % (w/v) LMNG. Cells
were broken using a 15 ml Dounce homogenizer and then rotated at 4°C for 1h. Cell lysate was
spun at 75,000 x g for 45 min at 4°C and the supernatant was filtered through a 0.45 μm filter
to remove insoluble matter. The filtered supernatant was incubated with washed M2 anti-FLAG
affinity gel (Sigma Aldrich) according to the manufacturer’s instructions for 3h with rotation at 4
°C. GLUT4 bound FLAG affinity gel was collected in a column and subjected to extensive
washing with 30 column volumes of buffer C (50 mM potassium phosphate, 350 mM KCl, 15 %
(vol/vol) glycerol, 3 mM EDTA, complete protease inhibitor (Roche), 0.1% (w/v) LMNG, pH7.4).
GLUT4 protein was eluted with six subsequent additions of 0.5 column volumes elution buffer
(buffer C containing 200 μg/ml FLAG peptide, 100 μg/ml 3x FLAG peptide (ApexBio)). Tags were
cleaved using TEV protease (plasmid purchased from Addgene) at a ratio of 1:20 TEV:GLUT4
overnight at 4°C in the presence of 1mM DTT. Based on SDS-PAGE and Blue BANDit protein
stain (Ameresco), GLUT4 protein after FLAG elution was > 90 % pure.
GLUT3 expression and purification
The gene for SLC2A3 (GLUT3) was purchased from the Mammalian Gene Collection
IMAGE:4396508. GLUT3 (N43A) was expressed using a construct consisting of the full length
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deglycosylation mutant SLC2A3 gene with a C-terminal purification tag containing a TEV
protease cleavage site, a 10xHis purification sequence and a FLAG tag in the expression vector
pFB-CT10HF-LIC (available from the SGC). Baculoviruses were produced by transformation of
DH10Bac cells. Spodoptera frugiperda (Sf9) insect cells in Sf-900 II SFM medium (Life
Technologies) were infected with recombinant baculovirus and incubated for 72h at 27°C in
shaker flasks.
Cell pellets (4 to 6 litres were used for each purification) from 1 litre of insect cell culture were
resuspended in 50ml of lysis buffer (50mM HEPES, pH 7.5, 200mM NaCl, Roche protease
inhibitor cocktail) and lysed by two passes through an EmulsiFlex-C5 homogenizer (Aventis).
Protein was extracted from cell membranes by incubation of the crude lysate with 1% (octyl
glucose neopentyl glycol) OGNG and 0.1% cholesteryl hemisuccinate (CHS) for 1h at 4oC. Cell
debris and unlysed cells were removed by centrifugation at 35,000g for 1h. Detergentsolubilized protein was purified by immobilized metal affinity chromatography by batch binding
to Co2+ charged TALON resin (Clontech) at 4°C for 1h. The resin was washed with 20 column
volumes of wash buffer (50mM HEPES, pH 7.5, 300mM NaCl, 5% glycerol, 20mM imidazole with
0.18% OGNG and 0.018% CHS) and eluted with lysis buffer supplemented with 250mM
imidazole. Imidazole was immediately removed using a PD10 column (GE Healthcare Life
Sciences) and elution buffer lacking imidazole and glycerol. The PD10 eluted protein was
treated with 20:1 (w:w, protein:protease) TEV protease overnight at 4°C. The TEV proteasecleaved protein was separated from the 6xHis-tagged TEV protease and uncleaved SLC2A3 by
incubation for 1h with TALON resin at 4°C. The resin was collected in a column and the flowthrough and initial wash with SEC buffer (20mM HEPES, pH 7.5, 100mM NaCl 0.12% OGNG and
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0.012% CHS) were concentrated in a 50kDa cut-off, 2ml PES concentrator (Corning) and further
purified by SEC using a Superdex 200 10/300GL column (GE Life Sciences) equilibrated with SEC
buffer collected at 2mg/ml. The molecular weight of each purified GLUT3 construct was
confirmed using an MSD-ToF electrospray ionization orthogonal time-of-flight mass
spectrometer (Agilent Technologies inc. Palo Alto, CA, USA).
SEC stability study. FLAG-purified GLUT4 was injected on to a Superdex 200 10/300 GL size
exclusion column (GE Healthcare) pre-equilibrated with 50 mM sodium phosphate, 150 mM
NaCl, 0.1 % LMNG, pH 7.4 to purify monomeric GLUT4. 40 µg of monomeric, SEC purified GLUT4
in 0.1% LMNG was then incubated in the absence and presence of various LMNG solubilized
lipids (0.02% w/v) for 1.5h at 40oC. Lipid dependent stabilization from heat induced
destabilization of GLUT4 was monitored by SEC. All SEC experiments were conducted at a flow
rate of 0.55 ml/min.
Liposome reconstitution. GLUT4 and GLUT3 containing liposomes were assembled according to
Kraft et al.

121

. Briefly, lipids were mixed in chloroform, dried down under argon, and residual

chloroform was removed under vacuum for 4h. The dried lipid film was resuspended in buffer D
(50 mM potassium phosphate, 130 mM NaCl, 10 % (vol/vol) glycerol, complete protease
inhibitor (Roche), pH 7.4) with rigorous vortexing under argon. Lipids were hydrated for 1 h at
room temperature using a vortexer set to the lowest speed followed by five freeze/thaw cycles
in liquid nitrogen and 37oC. The resulting multilamellar vesicles were extruded eleven times
through 200 nm polycarbonate filters (Whatman) using a mini extruder (Avanti Polar Lipids)
according to the manufacturer’s instructions to form large unilamellar vesicles. Triton X-100
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destabilized liposomes were rotated with purified GLUT4 at a lipid to protein ratio of 100-125:1
(w/w) for 45 min 4°C. Amberlite XAD-2 beads were added to remove detergent at a wet weight
of 15.5 mg beads per mg Triton X-100 and samples were then rotated at 4oC for 1 h. Fresh
beads were added 3 additional times for 1 h, once more overnight, and one additional time for
2 h the following day. After removal of all beads, liposomes were collected by
ultracentrifugation at 4°C for 1 h at 267,000 x g and resuspended in buffer containing 50 mM
potassium phosphate (pH 7.4), 130 mM KCl, pH 7.4 and complete protease inhibitor (Roche).
Samples were flash frozen with liquid nitrogen before storing samples at -80°C.
Liposome 3H-glucose uptake. Frozen liposomes containing purified GLUT4 or GLUT3 were
thawed at room temperature and subjected to three freeze/thaw cycles (liquid nitrogen/room
temperature) followed by extrusion through a 200 nm polycarbonate filter. Uptake was started
by adding 3H-D-glucose (1 µCi/ml, 200 μM cold D-glucose) (American Radiolabeled Chemicals)
to GLUT4 or GLUT3 proteoliposomes at room temperature. Transport was stopped at different
times with 5 ml ice-cold quench buffer (50 mM potassium phosphate (pH 7.4), 130 mM KCl, pH
7.4, and 100 μM phloretin) and then filtered by vacuum on a 0.2 μm mixed cellulose ester
filters (Avantec). Filters were subsequently washed with an additional 10 ml of quench buffer.
Scintillation fluid was added to the filters and the radioactivity counted. 3H-L-glucose (1 µCi/ml,
200 μM cold L-glucose) was used to determine nonspecific transport. Specific uptake was
calculated for all experiments by subtracting nonspecific 3H-L-glucose from 3H-D-glucose
uptake. In single time point experiments, specific uptake was normalized to amount of
transporter per reaction. The amount of transporter protein used in each uptake assay was
determined by analyzing aliquots of transporter containing liposomes along with a BSA
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standard curve on an SDS polyacrylamide gel stained with Blue Bandit protein stain and
quantified using an Odyssey infrared imaging system (LI-COR Biosciences). Data were fitted by
non-linear regression analysis using GraphPad Prism 6.0.
[3H]-D-glucose uptake in HEK293 cells. Stably transfected, tetracycline inducible HEK293S GnTIcells, expressing GLUT4 were grown on PEI treated 12-well plates to 90% confluency for uptake
experiments. 72 hours prior, protein expression was induced by 2 µg/ml doxycycline hyclate
and 5mM sodium butyrate while control cells were left uninduced. Cells were glucose-starved
in HEPES-buffered saline at room temperature 30 min prior to uptake measurements. Uptake
was initiated in HEPES-buffered saline at room temperature with the addition of [ 3H]-D-glucose
and then quenched after 40 s by washing rapidly in ice-cold PBS. Intracellular radioactivity was
quantified by liquid scintillation counting and normalized to total protein (BCA Protein Assay,
Pierce). GLUT4 specific uptake was calculated by subtracting uptake from uninduced cells from
that of induced cells.
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3.8 Figures

Figure 3.1. Protection of GLUT4 by anionic phospholipids from heat-induced destabilization.
SEC elution profiles of GLUT4 before and after heating in the presence or absence of several
anionic (a) and zwitteronic (b) lipids (0.02% w/v) as indicated by the color key. Protein
absorption was monitored at 280nm at a flow rate of 0.55 ml/min. Results are representative of
two independent experiments.
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Figure 3.2. Anionic phospholipids are required for GLUT4 and GLUT3 mediated D-glucose
uptake. (a,b) Time dependent specific uptake of 3H-D-glucose into GLUT4 containing PC
liposomes in the presence or absence of 15% (mol/mol) zwitterionic lipids (a) and anionic
phospholipids (b). Data are the mean ± s.e.m. of three independent experiments. (c) Specific
uptake of 3H-D-glucose into GLUT4 containing PC liposomes with increasing concentrations of
anionic phospholipids. Normalized uptake data (40s) are the mean ± s.e.m. of three
independent experiments. (d) Specific uptake of 3H-D-glucose into GLUT3 containing PC
liposomes in the presence or absence of 15% (mol/mol) anionic phospholipids. Normalized
uptake data (40s) are the mean ± s.e.m of four independent experiments. Asterisks denote
statistically significant differences (**, P ≤ 0.01) compared to PC control as determine by one-
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way ANOVA plus a posteriori Holm-Sidak test. (e) The chemical structure of each of the lipid
headgroups are colored coded for comparison.

Figure 3.3. Conical lipids stimulate GLUT4 and GLUT3 mediated glucose uptake. (a) Specific
uptake of 3H-D-glucose into GLUT4 containing PC liposomes in the presence of 10% (mol/mol)
POPA with increasing concentrations of POPE. Normalized uptake data (40 sec) are the mean ±
s.e.m. of five independent experiments. (b) Specific uptake of 3H-D-glucose into GLUT4
containing PC liposomes in the presence of 30% (mol/mol) POPE with increasing concentrations
of POPA. Normalized uptake data (40 sec) are the mean ± s.e.m. of five independent
experiments. (c) Chemical structures and overall shape of POPE and DAG. (d) Specific uptake of
3

H-D-glucose into GLUT4 containing PC liposomes in the presence of 10% (mol/mol) POPA with
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increasing concentrations of DAG. POPE titration results are shown for comparison. Normalized
uptake data (40 sec) are the mean ± s.e.m. of five independent experiments. (e) Specific uptake
of 3H-D-glucose into GLUT3 containing PC liposomes in the presence or absence of 15%
(mol/mol) POPA and/or 15% (mol/mol) POPE. Normalized uptake data (40 sec) are the mean ±
s.e.m. of five independent experiments. Asterisks denote statistically significant difference (ns,
P > 0.05; **, P ≤ 0.01; ****, P ≤ 0.0001) compared to PC control (unless otherwise indicated) as
determine by one-way ANOVA plus a posteriori Holm-Sidak test.
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Figure 3.4. Anionic and conical lipid effects on GLUT4 mediated glucose uptake are observed
in liposomes with a lipid composition comparable to that of the PM. (a) Phospholipid
composition of an idealized mammalian PM125. (b,c) Specific uptake of 3H-D-glucose into GLUT4
containing liposomes with lipid ratios reflecting the inner leaflet (b) or total PM (c) composition.
From left to right each bar represents an experiment where an additional lipid was added to the
previous lipid mix (Supplementary Tables 1 and 2). Normalized data (40s) are the mean ± s.e.m.
of five independent experiments. Asterisks denote statistically significant difference (ns, P >
0.05; *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001) as determine by one-way
ANOVA plus a posteriori Holm-Sidak test.
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Figure 3.5. Anionic and conical lipids increase the kcat but have no effect on the KM of both
GLUT4 and GLUT3. (a,b) POPA concentration dependent change of the kinetic parameters kcat
and KM for GLUT4 (a) and GLUT3 (b). Data are expressed as mean ± s.e.m. of four independent
experiments. (c,d) POPE concentration dependent change of the kinetic parameters kcat and KM
for GLUT4 (c) and GLUT3 (d). Data are expressed as mean ± s.e.m. of four independent
experiments. Kinetic parameters were determined from data shown in Supplementary Fig. 2 by
non-linear regression analysis and fitted using linear regression analysis.
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Figure 3.6. Mechanism of anionic and conical lipid effects on glucose transporters. (a) Model
of GLUT transporter interconversion and glucose transport in the presence and absence of
anionic and conical lipids. In the absence of anionic phospholipids, the transporter cannot
interconvert between inward and outward facing conformations. Added anionic phospholipids
bind to the transporter within the inner leaflet and trigger interconversion. Conical lipids lead
to an increase in the interconversion rate of the transporter in the presence of anionic
phospholipid. (b) Effect of anionic and conical lipids on lipid bilayer properties that influences
transporter dynamics. (c) Energy diagrams of the free energy for different transporter
conformations in the presence or absence of anionic and conical lipids.
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Supplementary Figure 3.1. Liposome reconstituted GLUT4 and GLUT3 transport D-glucose
with high specificity over L-glucose. (a) Time dependent uptake of specific 3H-D-glucose and
nonspecific 3H-L-glucose into GLUT4 containing PC:POPA:POPE (70:15:15) liposomes in the
presence or absence of 20 μM of the GLUT specific inhibitor cytochalasin B. Data are the mean
± s.e.m. of three independent experiments. (b) Time dependent uptake of specific 3H-D-glucose
and nonspecific 3H-L-glucose into GLUT3 containing PC:POPA:POPE (70:15:15) liposomes. Data
are expressed as mean ± s.e.m. of three independent experiments.
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Supplementary Figure 3.2. Influence of anionic and conical lipids on transporter kinetics for
GLUT4 and GLUT3. (a,b) D-glucose concentration dependent transport rate of GLUT4 (a) and
GLUT3 (b) containing PC liposomes in the presence of several concentrations of POPA.
Normalized data are expressed as mean ± s.e.m. of four independent experiments. (c,d) Dglucose concentration dependent transport rate of GLUT4 (a) and GLUT3 (b) containing PC
liposomes in the presence of several concentrations of POPE. Normalized data are expressed as
mean ± s.e.m. of four independent experiments.
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Supplementary Figure 3.3. D-glucose concentration dependent transport rate of GLUT4 in
HEK293 cells. Normalized data are expressed as mean ± s.e.m. of four independent
experiments. Michaelis constant KM was determined by non-linear regression analysis using
GraphPad Prism 6.0.
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Supplementary Table 3.1. Total PM lipid composition (mole %)
PC

+PS

+PE

+SM

+PI

+PA

eggPC

100

92

68

45

41.5

40.5

POPS

0

8

8

8

8

8

POPE

0

0

24

24

24

24

SM

0

0

0

23

23

23

PI

0

0

0

0

3.5

3.5

POPA

0

0

0

0

0

1

Supplementary Table 3.2. PM inner leaflet lipid composition (mole %)
PC

+PS

+PE

+SM

+PI

+PA

eggPC

100

84

47

33

26

24

POPS

0

16

16

16

16

16

POPE

0

0

37

37

37

37

SM

0

0

0

14

14

14

PI

0

0

0

0

7

7

POPA

0

0

0

0

0

2
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4.1 Abstract
Malaria and HIV infection are co-endemic in a large portion of the world and remain a major
cause of morbidity and mortality. Growing resistance of Plasmodium species to existing
therapies has increased the need for new therapeutic approaches. The Plasmodium glucose
transporter PfHT is known to be essential for parasite growth and survival. We have previously
shown that HIV protease inhibitors (PIs) act as antagonists of mammalian glucose transporters.
While the PI lopinavir is known to have antimalarial activity, the mechanism-of-action is
unknown. We report here that lopinavir blocks glucose uptake into isolated malaria parasites at
therapeutically relevant drug levels. Malaria parasites depend on a constant supply of glucose
as their primary source of energy and decreasing the available concentration of glucose leads to
parasite death. We identified the malarial glucose transporter PfHT as a target for inhibition by
lopinavir that leads to parasite death. This discovery provides a mechanistic basis for the
antimalarial effect of lopinavir and provides a direct target for novel drug design with utility
beyond the HIV-infected population.

4.2 Introduction
Despite aggressive world-wide efforts to eradicate malaria, this life-threatening disease
continues to affect over 200 million people per year, resulting in an annual death toll exceeding
half a million, mostly among African children 139. Currently, vaccination against malaria is not
available, while resistance against all known therapeutics is spreading 139. As a result, newer
antimalarial agents with novel mechanisms-of-action are urgently needed.
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The global prevalence of malaria and HIV infection largely overlap geographically. Combination
antiviral therapy that includes the HIV protease inhibitor (PI) lopinavir has been found to
dramatically decrease malaria incidence in a pediatric clinical population by 41%, suggesting a
direct effect of PIs on parasite replication 45. Indeed, lopinavir has demonstrated in vitro
activity49 against Plasmodium falciparum, the protozoan species responsible for most malaria
deaths48,139. In addition, lopinavir reduces the malaria liver stage burden in infected rhesus
monkeys in vivo at clinically relevant concentrations 140.
Despite ongoing efforts, the direct cellular target(s) of lopinavir responsible for its antimalarial
properties against P. falciparum remains unclear. PIs were originally designed as antagonists of
the viral aspartyl protease141. The malaria parasite requires a class of aspartyl proteases called
plasmepsins, which are necessary to degrade host hemoglobin 142 and direct export of malaria
export proteins143; however the antimalarial activity of PIs does not appear to be mediated
through plasmepsin inhibition47,50. Identifying the antimalarial mechanism-of-action of PIs is
imperative for finding a novel, clinically proven drug target and developing a new class of
lopinavir-like antimalarial drugs.
In clinical populations, prolonged use of PIs is associated with insulin resistance. Recent studies
have identified the molecular mechanism of this effect, which is mediated by direct binding of
PIs to the insulin-responsive facilitative glucose transporter GLUT4144–146. The human glucose
transporters share sequence homology with the essential P. falciparum glucose transporter,
PfHT. Similar to GLUT1 and GLUT4, the predicted topology of PfHT comprises 12
transmembrane helices, forming a central glucose permeation path. Key residues that are
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involved in glucose binding and transport are preserved between the human and malaria
glucose transporters44,147.
Intraerythrocytic malaria parasites depend on a constant supply of glucose as their primary
source of energy148. Not surprisingly, infected erythrocytes show a ~100 fold increase in glucose
consumption compared to uninfected erythrocytes 149. PfHT (PF3D7_0204700) is the principal
glucose transporter, transcribed from a single copy gene with no close paralogue44. PfHT has
been genetically validated as essential in Plasmodium parasites150 and has been independently
chemically validated as a novel drug target against malaria40,44.
Here we show that lopinavir inhibits glucose uptake into the P. falciparum parasite by blocking
PfHT at therapeutically relevant concentrations. This establishes a direct molecular target for
the antimalarial activity of lopinavir and validates the utility of targeting PfHT in novel drug
development.

4.3 Results
We compared the effect of currently FDA-approved HIV protease inhibitors on the replication
and survival of P. falciparum parasites in asexual erythrocyte cell culture. Consistent with prior
reports49,50 , all tested compounds inhibited parasite growth. Lopinavir was the most potent
inhibitor with an IC50 of 1.9 μM (Fig. 4.1a). We previously determined the inhibitory effect of
several HIV protease inhibitors on human glucose transport 68,144,146. Since HIV PIs inhibit human
glucose transport, we evaluated whether lopinavir might inhibit glucose uptake in isolated P.
falciparum parasites. We compared the uptake of radiolabeled 2-DOG in live parasites, isolated
from erythrocytes treated with vehicle, lopinavir, or the chemically unrelated PfHT inhibitor
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3361 (Fig. 4.2a)40. The O-3-hexose derivative compound 3361 [3-O-((undec-10-en)-yl)-Dglucose)] has previously been shown to selectively inhibit PfHT relative to several mammalian
sugar transporters and inhibit glucose uptake by the parasite, leading to inhibition of growth
and proliferation in vitro and in vivo40,43. We found that high concentrations of lopinavir
potently inhibited uptake of radiolabeled glucose by more than 70% compared to vehicletreated control, similar to the effect observed by the known PfHT inhibitor compound 3361. In
dose-response studies (Fig. 4.2b), we found that the inhibitory concentration (IC50)) of lopinavir
was 16 ± 4.2 μM, which is within the range of average serum peak levels of both adult and
pediatric patients treated with lopinavir/ritonavir 151–154.
To confirm that inhibition of malaria glucose transport was mediated through PfHT inhibition,
we developed and tested the effect of this PI on glucose transport in a PfHT-overexpressing
HEK293 cell line. HEK293 cells predominantly transport glucose using the facilitative transport
protein GLUT1. Using a PfHT sequence codon-optimized for mammalian cell expression, we
overexpressed the malarial hexose transporter protein and knocked down the expression of
GLUT1 using shRNA. In this engineered cell line, PfHT was the predominant hexose transporter
expressed (Fig. 4.3a). Glucose uptake in the PfHT overexpressing cell line was >5 times higher
compared to background cells that did not overexpress PfHT but were transduced with GLUT1
shRNA (Fig. 4.3b). We quantified the amount of [3H]-2-DOG accumulated in PfHT
overexpressing HEK293 cells in the presence of varying concentration of lopinavir and
determined an IC50 of 14 ± 2 μM. The IC50 values for the effect of lopinavir on glucose uptake in
both P. falciparum parasites and PfHT-overexpressing HEK293 cells are closely correlated,
consistent with a model in which inhibition of PfHT is responsible for decreased glucose uptake

78

and reduced parasite growth (Fig. 4.4). Supporting this model, blood stage P. falciparum is
acutely sensitive to reduced extracellular glucose concentrations 149. Since the measurement of
2-DOG uptake involves both the transport of this sugar and phosphorylation to 2-DOG-6-P, we
cannot fully exclude the possibility that lopinavir also inhibits the malarial hexokinase.
However, the observation that lopinavir inhibits 2-DOG uptake with different IC50s when
measured in HEK293 cells overexpressing different GLUTs (ranging from 3μM for GLUT4 to
32μM for GLUT1) suggests that hexokinase is not directly targeted.
To further investigate the mode of action of lopinavir on PfHT, we determined several
parameters by Michaelis-Menten kinetics. As expected, uptake of glucose is saturated with
increasing substrate concentration. The observed increase in K m with constant Vmax indicates
that lopinavir acts as a competitive inhibition of glucose uptake (Fig. 4.5).
To investigate the binding site of lopinavir on PfHT, we generated a model of the transporter
based on several crystal structures of homologous proteins using the I-TASSER webserver (Table
1). We selected a model with high cluster density in an inward conformation to determine the
lopinavir binding site by docking analysis. We created a docking volume covering the entire
protein to obtain unbiased results. Lopinavir was docked to the PfHT model using AutoDock
VINA via rigid receptor, flexible ligand docking. All docked poses of lopinavir were bound to
single binding pocket on the intracellular side of the glucose permeation path, preventing
glucose from entering and reaching its binding site (Fig. 4.6a). These results could be replicated
in several docking experiments using random seeds and different degrees of exhaustiveness,
strongly supporting this position as the lowest energy binding site. We compared the PfHTlopinavir putative binding site with the binding site of the structurally related protease inhibitor
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indinavir in the PfHT homologue GLUT4, published by Hresko et al. (Fig. 4.6b)68. The docking
experiments suggest that both indinavir and lopinavir bind to a structurally similar binding
pocket in their respective glucose transporters. Lopinavir binding within the glucose
permeation pathway is consistent with this drug acting as a competitive inhibitor of zero-trans
glucose uptake (Fig. 4.5). Although inhibition of GLUT4 by Indinavir requires drug binding from
the intracellular side of the transporter (35), lopinavir appears to have access to this domain
from the exofacial side of PfHT. Similar to the observed differences in isoform-selectivity of HIV
protease inhibitors for mammalian GLUTs (26), it is possible that steric influences of amino acid
side chains lining the glucose permeation pathway contribute to the ability of these drugs to
target PfHT.

4.4 Discussion
There is a compelling need for novel therapies for treatment of malaria. In particular, the
emergence and spread of resistance to artemisinin-based compounds threatens malaria control
efforts worldwide. Protease inhibitors, such as lopinavir, represent promising therapeutic leads
for new antimalarial development. Lopinavir has potent antimalarial activity in vitro and in
animal models48,140, and human studies of lopinavir-treated individuals in endemic areas
indicate antimalarial potency at clinically relevant doses 45. Importantly, many of the
pharmacologic challenges that slow antimalarial development have already been overcome
with lopinavir, which is orally bioavailable, available in suspension form (for pediatric use), and
suitable for once-daily dosing in combination with ritonavir.
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Our studies provide substantial evidence that inhibition of the malaria hexose transporter,
PfHT, is responsible for the antiparasitic effects of lopinavir. PfHT hexose transporter function is
known to be required for Plasmodium parasite development in culture and in animal
models40,43,44,150,155. We find that not only does lopinavir directly block glucose uptake into P.
falciparum parasites, it also inhibits glucose uptake in human cells engineered such that
majority of hexose transport is through heterologously expressed PfHT. Importantly, profound
reductions of glucose uptake into parasites and into PfHT-expressing human cells are achieved
at lopinavir concentrations well below therapeutically achieved drug levels 151–154.
Of note, even lower concentrations of both lopinavir and compound 3361 are required to
inhibit parasite replication than are required to inhibit glucose transport 40. This difference may
be explained by the reliance of parasites on a constant glucose supply. Plasmodium infection
increases cellular glucose consumption in erythrocytes nearly 100 fold, while parasite survival is
highly sensitive to reduced extracellular glucose concentrations 149. Thus, even partial inhibition
of Plasmodium glucose transporters may lead to growth inhibition and eventually death of the
parasite. PfHT may therefore represent a promising, parasite-specific “Achilles Heel” for targetbased drug discovery efforts. We cannot rule out the possibility that there are additional
targets of lopinavir in P. falciparum other than PfHT . The existence of additional drug targets, if
present, could delay the development of drug resistance, a major problem for malaria drugs.
However, observing this difference for both lopinavir and compound 3361, two structurally
unrelated drugs that inhibit PfHT-mediated glucose transport decreases the likelihood that they
would both also inhibit another secondary target.
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As agents designed for long-term suppression of HIV replication, lopinavir and other protease
inhibitors are well tolerated, with minor adverse events (mostly gastrointestinal) associated
with short-term use46. During chronic HIV treatment regimens that include PIs, disturbances in
glucose homeostasis and other metabolic changes that increase cardiovascular risk have been
reported156. In this HIV-infected population, it has been challenging to dissociate the direct
contributions of PIs from the influences of viral infection, other drug exposures (e.g. nucleoside
reverse transcriptase inhibitors), and associated environmental factors. Nevertheless, the in
vitro effects of PIs on the insulin-responsive facilitative glucose transporter GLUT4 correlate
directly with in vivo changes in insulin sensitivity, both in rodent models 157 and in humans158.
Fortunately, the effect of PIs on glucose tolerance is readily reversible following short-term
drug exposure, as required for treatment of malaria 157,158. However, the full spectrum of PImediated effects on the remaining GLUT isoforms remains unknown, and not all PIs appear to
have the same effect on GLUT4 activity159. Ideally, the development of drugs that selectively
target PfHT over mammalian GLUTs would provide highly selective inhibition of PfHT over the
mammalian GLUTs, resulting in a superior safety profile.
The development of high-throughput screening protocols targeting the Plasmodium glucose
transporter will help identify additional classes of PfHT antagonists. Several assays have been
developed by expressing PfHT in yeast or Leishmania44,150,160. In combination with these prior
studies, our current findings confirm that PfHT is an attractive, druggable target for malaria.
Our development of a PfHT overexpressing HEK293 cell line and demonstration that this system
can reliably test for drug-mediated inhibition of the malarial glucose transporter can
significantly aid candidate drug screening. Complementing a high-throughput approach is the
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opportunity for structure-based design. This can allow for higher affinity and selectivity to the
plasmodium transporter while minimizing effects on mammalian glucose transporters (GLUTs).
GLUT1 is the most extensively characterized of the human GLUTs and a crystal structure of this
protein was recently reported13. In the absence of structural data for PfHT and the other
known GLUTs, it has been necessary to rely upon molecular modeling based on the structures
of related bacterial and mammalian transporter. Although, our docking results are consistent
with the previously identified HIV protease inhibitor binding site in the closely related
transporter GLUT468, we cannot exclude the possibility that lopinavir binds to a distinct binding
site only accessible in an outward open conformation of PfHT. Testing this possibility will
generate valuable data once a homologues transporter is crystallized in the outward open
conformation. Future efforts to establish a comprehensive structure-activity profile for the
inhibition of PfHT and the human GLUTs may provide valuable information about the feasibility
of this approach. Investigation of potential additive or synergistic effects of PfHT inhibitors with
existing anti-malarial agents or other compounds that inhibit parasite metabolism will also be
of great interest.
In summary, the identification of lopinavir as a clinically meaningful inhibitor of the essential
malaria hexose transporter PfHT provides a strong rationale and molecular basis for future
antimalarial development efforts targeting this protein. Because PfHT inhibition retards both
the liver and mosquito-stage development of rodent malaria parasites 42, novel PfHT inhibitors
hold great promise for use in malaria treatment and as transmission-blocking agents. The
existing pharmacokinetic and safety data for lopinavir should allow rapid assessment of the
suitability and efficacy of this agent in non-HIV infected patient populations. Understanding the
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molecular target of lopinavir in P. falciparum will be key to any necessary medicinal chemical
optimization of lopinavir and related protease inhibitors, repurposed for use as antimalarials.

4.5 Material and Methods
Materials
[14C]-2-deoxy- glucose (2-DOG) was purchased from PerkinElmer. [3H]-2DOG was purchased
from American Radiolabels Inc. PfHT DNA was codon optimized and synthesized by Life
Technologies (Grand Island, NY). GLUT1 shRNA was obtained through the RNAi core at
Washington University, School of Medicine. HEK293 cells were acquired from the American
Type Culture Collection. HIV protease inhibitors were obtained through the NIH AIDS Reagent
Program, Division of AIDS, NIAID, NIH. Compound 3361 was kindly donated by Sanjeev Krishna
(Centre for Infection, Division of Cellular and Molecular Medicine, St. George's, University of
London).
Malaria tissue culture
The P. falciparum strain strain 3D7 was obtained from the Malaria Research and Reference
Reagent Resource Center (MR4, ATCC, Manassas, Virginia). Unless otherwise stated, P.
falciparum strains were cultured at 37°C in a 2% suspension of human erythrocytes in RPMI1640 medium (Sigma-Aldrich, SKU R4130) supplemented with 27 mM sodium bicarbonate, 11
mM glucose, 5 mM HEPES, 1 mM sodium pyruvate, 0.37 mM hypoxanthine, 0.01 mM
thymidine, 10 µg/mL gentamicin, and 0.5% Albumax (Life Technologies) in a 5% O2/ 5% CO2 /
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90% N2 atmosphere, as previously described 161,162. Culture growth was monitored by
microscopic analysis of Giemsa-stained blood smears.
Drug and glucose sensitivity of P. falciparum
Asynchronous P. falciparum cultures were diluted to 1% parasitemia and were treated at a
range of concentrations of inhibitor or glucose. Growth inhibition assays were performed in
opaque 96-well plates at 100 µL culture volume. After 3 days, parasite growth was quantified
by measuring DNA content using Picogreen (Life Technologies), as previously described 163.
Picogreen fluorescence was measured on a FLUOstar Omega microplate reader (BMG Labtech)
at 485 nm excitation and 528 nm emission. IC 50 values were calculated by nonlinear regression
analysis using GraphPad Prism software.
Stable expression of PfHT
HEK293 cells were stably transfected with codon optimized PfHT DNA in the pcDNA 3.1(-) hygro
plasmid (Life Technologies) as described earlier 164. After selection with hygromycin, 10 colonies
were grown to near confluency in 4cm tissue culture dishes and the highest expresser of PfHT
was selected using [3H]-2DOG uptake and quantitative RT-PCR (as described below).
Short hairpin RNA lentiviruses for GLUT1 knockdown
293T packaging cells were cotransfected with VSVg and Delta 8.9 packaging plasmids plus
shRNA lentiviral plasmids targeting GLUT1 (NM_006516.1-2310s1c1) using Optifect transfection
reagent (Life Technologies). The media was changed 12 hours after transfection and
supernatants (10 ml) were harvested every 24 hours for 72 hours and kept at 4°C until they
were pooled, filtered through 0.45 μm syringe filters, aliquoted and stored at -80°C until use.
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HEK293 wild-type cells or HEK293 cells stably expressing PfHT were infected by exposing them
to viral supernatant for 48 hours, then replacing with selection media (containing 5 μg/ml
puromycin).
Quantitative PCR analysis
Total RNA was isolated using the TRIzol Plus RNA Purification System (Life Technologies). RNA
was reverse transcribed using the qScript cDNA SuperMix (Quanta Biosciences, Gaithersburg,
MD). Quantitative RT-PCR was performed using the Power SYBR® Green PCR Master Mix
(Applied Biosystems) as described previously165.
2-DOG uptake into P. falciparum and HEK293 cells
Uptake of [14C]-2DOG into isolated parasites was determined at room temperature using the
methods described previously43. Lopinavir and compound 3361 were added 5min prior to the
addition of [14C]-2DOG (0.2 µCi/mL final concentration). Uptake of [3H]-2DOG into HEK293 cells
was measured in phosphate buffer at 37°C for 5min as described previously 68.
Statistical analyses
The data are reported as means ±SEM. Differences between control and experimental values
were determined by one-way ANOVA analysis.
Modeling of PfHT and docking of lopinavir
PfHT structure was predicted using the I-TASSER webserver90–92. The webserver was amongst
top scorers of the Server Section of the 7th (2006), 8th (2008), 9th (2010), 10th CASPs (2012),
and 11th CASPs (2014), a community-wide experiment for testing the state-of-the-art of protein
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structure predictions. We chose a model that resembled the inward open conformation.
Docking was performed using AutoDock Vina93. The receptor was prepared using MGLTools
version 1.5.6 and the ligand lopinavir was prepared using ArgusLab. The docking process was
repeated with number of modes of 50 and increasing exhaustiveness of 25, 50 and 100. The
results in each attempt were 20 similar docked poses. Docked poses were displayed using
PyMOL version 1.7.4.0.
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4.8 Figures

Figure 4.1. Comparison of HIV protease inhibitors’ potency on P. falciparum growth inhibition
(a) IC50 comparison of HIV protease inhibitors on growth P. falciparum in blood culture. IC50 was
calculated using non-linear regression analysis and is expressed as means with 95% confidence
interval. (b) Chemical structures of the three most potent inhibitors HIV protease inhibitors of
PfHT mediated glucose uptake.
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Figure 4.2. Uptake of [14C]2DOG by isolated P. falciparum trophozoites (a) in the presence of
lopinavir (100 μM), compound 3361 (200 μM) or vehicle or (b) at increasing concentrations of
lopinavir. The uptake was quenched after 2 minutes. IC 50 was calculated using non-linear
regression analysis. Uptake data are expressed as means ±SEM. A 30sec or 1min time point
would have been a more accurate measurement of initial rates however, we chose the longer
time point to enhance the uptake signal as the degree of non-linearity will probably not greatly
affect the calculated IC50 value.

89

Figure 4.3. PfHT is the predominant transporter in engineered HEK293 cells. (a) mRNA
expression levels of glucose transporter proteins in HEK293 wild-type (WT), GLUT1 knock-down
(KD) and GLUT1 KD + PfHT overexpressing (OE) cells. mRNA levels were determined via
quantitative PCR and levels are displayed in copy number per ng of cDNA. Data are expressed as
means ±SEM. (b) Comparing specific activity of glucose uptake in HEK293 cells expressing
GLUT1 shRNA and plus and minus overexpression of PfHT. Data are expressed as means ±SEM
(*P<0.05, ***P<0.001; one-way ANOVA analysis).
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Figure 4.4. Specific activity of glucose uptake in HEK293 cells stably expressing PfHT and
GLUT1 shRNA at different lopinavir concentrations. Glucose uptake was determined by
quantifying the amount 2-DOG accumulated in HEK293 cells and normalizing to time and total
protein. The experiment was repeated in an identical background cell line that does not
overexpressing PfHT. Normalized specific activity of PfHT overexpressing cells was adjusted for
non-PfHT specific glucose uptake by subtracting background uptake. Data are expressed as
means ±SEM. IC50 was calculated using non-linear regression analysis.

91

Figure 4.5. Kinetic analysis of inhibition of glucose uptake by PfHT by lopinavir. 3H-2-DG
uptake was determined in the presence of various concentrations of lopinavir and substrate.
Uptake was quenched after 2 minutes. Data was fitted to the Michaelis-Menten equation by
non-linear regression using GraphPad Prism 6 to obtain Km and Vmax values and was
transformed and plotted as double-reciprocal Lineweaver-Burk plot using GraphPad Prism 6.
Uptake data are expressed as means ±SEM (n=3).
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Figure 4.6. Docking analysis of HIV protease inhibitors with glucose transport proteins. (a)
Lopinavir docked within the glucose permeation channel of PfHT. Lopinavir (pink) is docked in
several poses to the inward open conformation of PfHT. The amino-terminal half of PfHT is
colored blue and the carboxyl-terminal half is green. The depicted 40 poses occupy a single
binding pocket and are representative of the results of several rounds of docking analysis. (b)
Indinavir docked within the glucose permeation channel of GLUT4. Indinavir (pink) is docked to
the inward open conformation of GLUT4 (published in 68). The amino-terminal half of GLUT4 is
colored blue and the carboxyl-terminal half is green.
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Table 4.1. Top 10 templates used by I-TASSER. Rank of templates represents the top ten
threading templates used by I-TASSER. Ident1 is the percentage sequence identity of the
templates in the threading aligned region with the query sequence. Ident2 is the percentage
sequence identity of the whole template chains with query sequence. Cov. represents the
coverage of the threading alignment and is equal to the number of aligned residues divided by
the length of query protein. Norm. Z-score is the normalized Z-score of the threading
alignments. Alignment with a Normalized Z-score >1 mean a good alignment and vice versa.

Rank

PDB
Hit

Iden1

Iden2

Cov.

Norm.
Z-score

1

4pypA

0.28

0.26

0.87

3.85

2

4gbyA

0.26

0.26

0.88

5.79

3

4pypA

0.27

0.26

0.87

5.39

4

4gc0A

0.25

0.26

0.88

3.91

5

4gc0A

0.26

0.26

0.89

3.65

6

4pypA

0.28

0.26

0.87

5.35

7

4gc0A

0.26

0.26

0.89

4.83

8

4pypA

0.29

0.26

0.87

6.61

9

4pypA

0.28

0.26

0.87

4.68

10

4pypA

0.28

0.26

0.87

4.82
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5.1 Abstract
The glucose transporter PfHT is essential to the survival of the malaria parasite Plasmodium
falciparum and has been shown to be a druggable target with high potential for
pharmacological intervention. Identification of compounds against novel drug targets is crucial
to combating resistance against current therapeutics. Here, we describe the development of a
cell-based, high-throughput assay that directly measures the ability of a compound to inhibit
glucose transport by PfHT. This assay determines the intracellular glucose concentration via an
expressed glucose sensor protein that changes its fluorescence resonance energy transfer
(FRET) intensity in a glucose-dependent manner. This allows for the direct assessment of the
ability of a compound to inhibit glucose uptake with high accuracy (Z’-factor of >0.8), while
eliminating the need for radiolabeled substrates. Furthermore, we have adapted this assay to
counter screen PfHT hits against the human orthologues GLUT1, 2, 3 and 4. We report the
identification of several hits after screening the Medicines for Malaria Venture (MMV) Malaria
Box, a 400 compound library of known inhibitors of parasite blood stage growth. Hit
compounds were verified and characterized by determining the IC50 for inhibition of
radiolabeled glucose uptake into isolated P. falciparum parasites. One of our hits, compound
MMV009085, shows high potency and ortholog selectivity, thereby successfully validating our
assay for large-scale application.

5.2 Introduction
Malaria is estimated to have killed half of all the people who have ever lived and remains a
major threat, affecting over 200 million people per year 139,166. Beyond the staggering effect of
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this disease on human life, malaria also cripples economic development and burdens the health
care systems of malaria endemic countries 167. The emergence of parasites with resistance to
even the most potent existing anti-malarial drugs like artemisinins 168 has made paramount the
development of novel drugs that target essential pathways for parasite survival. Glucose is the
primary source of energy for blood-stage parasites as they almost exclusively rely on glycolysis
for survival The malarial glucose transporter, Plasmodium falciparum hexose transporter
(PfHT), first cloned by Woodrow et al. in 1999147 and shown to be essential for parasite
survival155, is one highly promising molecular target. PfHT has been chemically validated as an
antimalarial target, as a glucose analog (compound 3361) has been found to inhibit PfHT with
high selectivity over the human orthologue GLUT1 and also inhibits asexual intraerythrocytic
growth in culture

40

. Compound 3361 is also active against P. berghei liver and transmission

stage parasites in infected mice42. However, while 3361 validates efforts to target PfHT, this
compound is not itself considered drug-like and is therefore not a valid candidate for lead
development

169

. We have recently extended these earlier findings by identifying PfHT as a

direct molecular target of the HIV protease inhibitor lopinavir, thus providing a link between
lopinavir use and decreased malarial transmission in areas where HIV and malaria are coendemic

170

. However, lopinavir has a relatively high IC50 of 16 μM in parasites and shows

higher selectivity for the human insulin responsive glucose transporter GLUT4 over PfHT

170

.

Therefore, novel therapeutics targeting PfHT with improved potency and selectivity are
required.
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Results
Assay development
To develop a robust and efficient high-throughput assay to identify novel PfHT inhibitors,
consideration was given to simplicity, sensitivity, scalability, cost, and reliability. Current assays
for transporter inhibition in high-throughput format generally employ radiolabeled substrate or
cell death of a transporter-overexpressing cell line as a readout171,172. Both formats have
significant limitations. Although measuring the uptake of radiolabeled substrate generally yields
quantitative, highly reproducible results and minimizes false positives (e.g. fluorescent
compounds), the use and disposal of radiolabels are expensive and handling radioactive
substances requires increased safety precautions. Alternatively, using cell death of an
engineered cell line that requires transporter function for survival is an elegant way to simplify
the readout. In both cases, these assays fail to discriminate between compounds that kill the
cells through transporter inhibition and compounds that kill through other mechanisms,
resulting in false positive results as high as 97.8% 160.
Our goal was to design an assay that would use transporter function as a direct, highly
reproducible readout without the use of radiolabels. We therefore designed a cell line that
transports glucose almost exclusively through PfHT and combined this with an intracellular
glucose sensor protein that translates glucose concentration into a fluorescence signal as
readout. We used the glucose sensor FLII12Pglu-700µδ6 (FLIP), initially developed and
characterized in the laboratory of Wolf Frommer as readout for measuring cellular glucose
influx173. This genetically encoded optical glucose sensor consists of three protein domains: A
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central glucose-binding domain that is coupled terminally to a cyan fluorescent protein (CFP)
and a yellow fluorescent protein (YFP). Upon excitation of CFP, energy is transferred to YFP
through FRET. When glucose enters the cell, it binds to the glucose binding domain, leading to a
conformational change that brings the two fluorescent proteins closer together and increases
FRET (Fig. 5.1). Using the human embryonic kidney cell line HEK293, we created a reporter cell
line, stably expressing PfHT in conjunction with FLIP (PfHT-FLIP cells). HEK293 cells are known to
exhibit relatively low endogenous glucose uptake173. To further reduce background levels of
glucose uptake, we knocked down the primary endogenous transporter isoform GLUT1 using
siRNA, yielding a cell line that predominantly transports glucose through PfHT 170. We tested the
function of our engineered cell line by measuring the time course of glucose uptake via readout
of the YFP/CFP ratio (FRET ratio) in the presence and absence of known PfHT inhibitors. Upon
addition of the HIV protease inhibitor lopinavir (Fig. 5.2a), previously identified to block PfHTmediated glucose uptake, the PfHT-FLIP cells showed decreased FRET ratio upon the addition of
D-glucose, consistent with inhibition of radiolabeled D-glucose uptake in these cells170.
Additionally, we confirmed concentration-dependent inhibition of glucose uptake in PfHT-FLIP
cells by the glucose transport inhibitor cytochalasin B (CB) as previously shown in Xenopus
laevis oocytes147. In PfHT-FLIP cells, CB causes a maximal decrease in FRET ratio of 75% at 50
μM consistent with radiolabeled uptake inhibition in oocytes 147 and complete inhibition of Dglucose uptake at 200 μM (Fig. 5.2b), making CB an ideally suited positive control for assay
optimization and high-throughput screening.
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Assay optimization
We optimized the assay for high-throughput application in a 96-well format using the Z’-factor
and the coefficient of variation (CV) as measures of assay robustness

174

. For these

measurements, half of the plate was treated with 200 μM CB as positive control and the other
half with vehicle prior to the addition of D-glucose. Cells adhered tightly to the plate bottom
after treatment of the plate with the highly branched polymer PEI that acted as adhesive,
thereby preventing cells from dislodging during washing and buffer exchange steps. After
optimization of assay temperature, fluorescence read mode, cell density and cell plating
protocol we were able to routinely obtain a Z’-factor of >0.8 (a perfect assay would have a Z’factor of 1.0) and CV of 2% (Fig. 5.3).
Screening of the Malaria Box compound library
In order to test our assay system in an automated setting for high-throughput application, we
selected the MMV Malaria Box, a small library of 400 compounds previously shown to have a
cytotoxic effect on malaria parasites 175. This library contains chemically diverse compounds
with half of the compounds having drug-like properties and the other half having been selected
as molecular probes. As this compound set was selected for their cytotoxic activity against
blood-stage malaria parasites, the molecular drug targets remain to be determined. The
rationale for choosing this library was to identify compounds that inhibit parasite growth mainly
or partially through blockade of PfHT-mediated glucose uptake, since deorphanization of these
compounds will aid in further PfHT-specific drug development.
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We screened the Malaria Box at 10 μM drug concentrations in triplicate and selected hits that
decrease the FRET ratio by more than 40% with vehicle-treated cells set to 100% and cells
treated with 200 μM CB set to 0%. Since this assay is based upon changes in FRET, we reduced
the number of fluorescent, false positive hits, by determining the FRET ratio of compounds
without cells present. After false positive elimination, we identified 6 compounds as primary
hits. Hit confirmation was ascertained by determining the IC 50 for glucose uptake into isolated
P. falciparum parasites from blood culture using radiolabeled D-glucose. Five of the six primary
hits could be confirmed to inhibit glucose uptake into P. falciparum parasites in the low
micromolar range (Table 1) with compound MMV665941 showing only partial maximal
inhibition (Fig. 5.4). Comparison of the IC50 for glucose uptake inhibition with the IC50 for
cytotoxicity in blood culture parasites indicates that only the most potent hit, MMV009085,
inhibits parasite growth mainly through PfHT inhibition (Table 1). For the other confirmed hits,
glucose uptake inhibition contributes to the cytotoxic effects of these compounds but is most
likely not the main mechanism of action (Table 1).
To establish selectivity of these hits for PfHT over human orthologues, we cross-validated the
inhibition of GLUTs 1, 2, 3 and 4 by the confirmed hits. Using the same HEK293-FLIP cell line, we
overexpressed each of the individual class I transporters. With the exception of GLUT1-FLIP, the
other GLUT cell lines were also treated with GLUT1 specific siRNA to reduce background glucose
uptake. We confirmed that the overexpressed GLUT was the main glucose transporter
expressed in each cell line by comparing the cDNA copy number of all human SLC2A genes via
qPCR (Fig. 5.5). We determined the inhibitory effect of the five confirmed hits on all four human
class I GLUTs at the IC50 concentration for PfHT-mediated glucose uptake inhibition. Only
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compound MMV009085, the most potent hit with an IC50 of 1.8 μM for PfHT-mediated glucose
uptake, showed significantly less inhibition of the human GLUTs compared to PfHT (Fig. 5.6a).
Comparison of the IC50s for glucose uptake inhibition, mediated by either the human GLUTs or
PfHT, revealed a more than 10-fold higher selectivity of MMV009085 for PfHT over human
orthologues (Fig. 5.6b). Although MMV009085 is considered a probe-like molecule, its high
potency in inhibiting both glucose uptake and growth of the parasites as well as its high
selectivity for PfHT over human orthologues makes this compound a potential candidate for
lead optimization. Additionally, it demonstrates that our newly developed assay can identify
glucose transporter-specific inhibitors and further distinguish compounds with high selectivity
for their target over its orthologues or isoforms.
Discussion
We describe here the development of a new high-throughput screening assay that uses the
ability of a compound to directly inhibit glucose uptake, mediated by either the malarial glucose
transporter PfHT or a human GLUT transporter as readout to identify novel and selective antimalarial agents. Our results show high reproducibility with a CV of 2% and good separation of
hits from background with a Z’-factor of >0.8, which is indicative of an excellent assay for high
throughput screening174. Additionally, this assay does not require radioactive labels, thereby
increasing throughput and ease-of-use while significantly decreasing cost. This is especially
important in the field of infectious diseases affecting people in the developing world, where
funding is generally provided by nonprofit organizations 176. Our initial screen of a small, 400
compound library resulted in four verified hits. Although the rate of false positives (2) after the
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initial round of screening is significantly lower than in similar assays 160 it can still be improved
by selecting a higher threshold of FRET ratio reduction, especially when screening a larger
library or using different detection methods like fluorescence lifetime 177,178. The hits identified
in this screen include three compounds (MMV009085, MMV020548, MMV665879) that were
previously identified by Ortiz et al.160 to selectively inhibit glucose uptake, but not proline
transport, in PfHT-overexpressing Leishmania mexicana. Compound MMV009085 consistently
exhibited the highest potency in inhibiting PfHT-mediated glucose uptake in both assays. In our
screen, reduction in FRET ratio correlated well with inhibitory potency of the compound with
the most potent inhibitor MMV009085 showing the strongest decrease in FRET ratio.
The quality of hits in drug discovery projects is crucial in improving the odds of developing a
successful candidate for clinical application, especially as downstream investments into the hits
that are selected for lead development are significant both in terms of funding and time 176.
Therefore, target-based screens are highly advantageous to phenotypic screens as they allow
lead identification and optimization that are directed towards the malarial target protein versus
human orthologues. We adapted our assay system to include cross-screening of PfHT-specific
hits against human glucose transporters. The facilitative glucose transporters GLUT1-4 are
fundamentally important for human glucose homeostasis as they are primary glucose
transporters in most tissues109. PfHT and the human transporters share a common MFS fold and
show a sequence similarity of close to 50%. The significance of the human GLUTs and their close
homology to the malarial glucose transporter make it crucial, but potentially challenging to
identify drugs with high orthologue selectivity. By replacing PfHT with human GLUTs, our
HEK293 cell based assay system successfully distinguished PfHT specific from orthologue non-
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specific inhibitors and identified a compound that showed a 19 to >250-fold high selectivity for
PfHT over the human GLUTs.
An additional advantage of target-directed screening is the opportunity for structure-based
rational drug design to aid in lead compound optimization. For the mammalian glucose
transporters, recent progress has been made in solving the crystal structures of several
isoforms in both inward and outward conformations 25–27. Furthermore, our prior work has
provided evidence for the binding pocket that mediates transporter inhibition by HIV protease
inhibitors81,170,179. This has been used to model lopinavir binding to a model of PfHT 170. Taken
together, these data provide a framework for iterative structure activity analysis of compounds
identified via our newly developed high-throughput screening assay.
In addition to using the GLUT-expressing FLIP cells lines for selecting orthologue-specific PfHT
inhibitors, these cell lines can be used to identify GLUT-specific inhibitors with isoform
selectivity with applications beyond anti-malarial therapy. Several types of tumors have been
shown to overexpress specific GLUT isoforms that mediate the transport of high levels of
glucose to malignant cells that have undergone metabolic rearrangement and primarily
metabolize glucose through aerobic glycolysis (known as the Warburg effect) 29,31. Many cancer
cells express transporter isoforms that are not found in these tissues in non-malignant
conditions. Among the class 1 facilitative glucose transporters, GLUT1 is most abundantly
expressed in cancers from breast, brain, lung, colorectal, and bladder30. Inhibition of GLUT1 has
already been shown to exert antineoplastic effects, both in vitro and in vivo32,33 making it a
promising target for cancer therapy. Expression of the glucose transporters GLUT2, GLUT3 and
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GLUT4 is also upregulated in various tumors, among them several types that are difficult to
treat and are associated with low survival rates like lung, pancreatic, and liver tumors 30,31,180.
Our cell-based, target-specific screen is designed to be easily adaptable to mediate glucose
transport through selectively expressed transporter isoforms. This versatility combined with a
robust, easily detectable readout significantly increases the feasibility of screening large
compound libraries to identify isoform-specific GLUT inhibitors that can be further developed
into drugs for either stand-alone or adjunct cancer therapy.

5.5 Material and Methods
Materials
[14C]-2-deoxy- glucose (2-DOG) and [3H]-2-DOG were purchased from American Radiolabels Inc.
GLUT1 shRNA was obtained through the RNAi core at Washington University School of
Medicine. HEK293 cells were acquired from the American Type Culture Collection (ATCC).
Lopinavir was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH.
HEK293 cell line generation
HEK293 cells were transfected with pcDNA3.1 FLII12Pglu-700uDelta6 (Addgene), containing the
FRET glucose sensor (HEK293-FLIP) using Optifect Reagent (Life Technologies) according to
manufacturer’s specifications. Cells that stably integrated the gene were selected using G418
(Sigma Aldrich) and highest expressers were identified using Fluorescence Activated Cell Sorting
(FACS). These cells were then stably transfected with PfHT, human GLUT1 (hGLUT1), human
GLUT2 (hGLUT2), human GLUT3 (hGLUT3) or human GLUT4 (hGLUT4) DNA in the pcDNA 3.1(-)
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hygro plasmid (Life Technologies) as described previously170. In all cell lines except for HEK293
overexpressing hGLUT1 cells, native hGLUT1 was knocked down using siRNA as described in 170.
mRNA transcript levels of all known human GLUTs were determined in the four GLUT
overexpressing cell lines as described below using qPCR. PfHT expression levels in
overexpressing cells were previously characterized 170.
RNA isolation and quantitative PCR
Total RNA was isolated using the TrizolW Plus RNA Purification System (Invitrogen), and one
microgram of RNA was reverse transcribed using qScript cDNA Supermix (Quanta Biosciences).
Quantitative RT-PCR was performed using Power SYBR Green PCR Master Mix (Applied
Biosystems). Each reaction was run in triplicate using the primers listed in Table 2.
Quantifications were performed with standard curves generated using plasmids containing
each human GLUT (DNASU).
Assay optimization and high throughput screening
Several conditions were optimized to increase the sensitivity and reliability of the assay. PfHTFLIP cells were plated 48 h prior to the assay in black opaque 96-well plates (Greiner Bio-One)
at 30,000 cells/well. 96-well plates were pretreated with 25 μg/ml Polyethylenimine (PEI, 750
kDa, Sigma Aldrich) solution containing 150 mM NaCl to maintain cell adhesion during washing
steps. After 20 min incubation at room temperature (RT), PEI was aspirated and wells were air
dried for 5 min. After cell plating, plates were then left in the sterile hood at RT for 45 min
before transfer to the incubator to reduce edge effects. Compound screening was performed
using the integrated and automated screening system (Beckman Coulter) at the Washington
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University High Throughput Screening Core. We used the SAMI EX software (Beckman Coulter)
to design and execute the screening protocol. The Malaria Box (Medicines for Malaria Venture)
compound library was prediluted in glucose-free HEPES buffered saline solution (HBSS) (146
mM NaCl, 4.7 mM KCl, 0.6 mM MgSO4, 1.6 mM NaHCO3, 0.13 mM NaH2PO4, 2.5 mM CaCl2, 20
mM HEPES, pH 7.3) using the BiomekFX liquid handler (Beckman Coulter). We prepared a 1:100
dilution of 1 mM stock solution for 10 µM final concentration.
To start the high throughput assay, cells were washed twice with 150 μl HBSS per well using the
ELx405 Plate Washer (Biotek). Cells were starved in HBSS for 30 min at RT followed by
aspiration of the HBSS from cell plates using the ELx405 Plate Washer. Cells were treated with
45 µl of diluted compound using the BiomekFX (with 3 replicate cell plates for each library
plate) and incubated for 6 min at RT. To start the uptake, 5 µl of 100 mM glucose was added to
the wells (final concentration 10 mM) using a Multidrop384 dispenser (Thermo Fisher
Scientific). After incubation at RT for 120 min, fluorescence was measured using the 2102
EnVision Multilabel Plate Reader (Perkin Elmer) at excitation 436 nm (CFP) and emissions 485
nm (CFP) and 535 nm (YFP).
P. falciparum culture
P. falciparum strain 3D7 was obtained from the Malaria Research and Reference Reagent
Resource Center (MR4). P. falciparum parasites were cultured in a 2% suspension of human
erythrocytes and RPMI 1640 (Sigma Aldrich) medium supplemented with 27 mM sodium
bicarbonate, 11 mM glucose, 5 mM HEPES, 1 mM sodium pyruvate, 0.37 mM hypoxanthine,
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0.01 mM thymidine, 10 µg/ml gentamicin, and 0.5% albumax (Gibco) at 37°C, 5% O 2/ 5% CO2 /
90% N2 atmosphere as previously described 161,162.
P. falciparum growth inhibition assays
Asynchronous P. falciparum cultures were diluted to 1% parasitemia and were treated with
compounds at concentrations ranging from 9.8 nM - 20 μM. Growth inhibition assays were
performed in 100 µl cultures in opaque 96-well plates. Parasite growth was quantified after 3
days by measuring DNA content using PicoGreen (Life Technologies)

163

. Fluorescence was

measured by a FLUOstar Omega microplate reader (BMG Labtech) at 485 nm excitation and
528 nm emission. IC50 values were calculated by nonlinear regression analysis using GraphPad
Prism software.
Glucose uptake into P. falciparum parasites
P. falciparum strain 3D7 was cultured in 100 mm tissue culture dishes (Techno Plastic Products)
in a 2% suspension of human erythrocytes and RPMI 1640 medium until reaching > 5%
parasitemia. Cells were pelleted via centrifugation and resuspended in RPMI. Uptake of [14C]-2DOG into isolated parasites was determined at RT using the methods described previously43.
Test compounds were added 5 min prior to the addition of [14C]-2-DOG (0.2 µCi/ml final
concentration). Uptake was quenched after 1 min. Data were fit by nonlinear regression
analysis using GraphPad Prism software.
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Glucose uptake into HEK293 cells
Uptake of [3H]-2-DOG into HEK293-FLIP cell lines was measured in HEPES-buffered saline at RT
for 4 min as described previously81. Data were fit by nonlinear regression analysis using
GraphPad Prism software.
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5.8 Figures

Figure 5.1. Generation of cell lines for high throughput screen. (a) HEK293 cells were stably
transfected with the P. falciparum hexose transporter (PfHT), the glucose sensor FLII12Pglu700uDelta6 and treated with siRNA directed at hGLUT1 to reduce background glucose uptake.
(b) Glucose FRET sensor expressed in PfHT expressing cells. In the absence of glucose, CFP and
YFP are further apart and the amount of energy transferred to from the donor CFP to the
acceptor YFP that is emitted as light (FRET signal) is low. Glucose binding to the
glucose/galactose binding domain (MglB) leads to a conformational change that brings CFP and
YFP closer together, resulting in an increase FRET signal.
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Figure 5.2. Time dependent change in FRET ratio (YFP emission/CFP emission) after addition
of glucose to PfHT-FLIP cells (a) in the presence or absence of lopinavir or (b) in the presence or
absence of cytochalasin B (CB).
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Figure 5.3. Z’ factor determination. FRET ratio per well of 96-well plate, with 48 wells treated
with 200μM CB (inhibitor) and 48 wells treated with vehicle. Z’-factor and the coefficient of
variation (CV) as were determined from the average and standard deviation of each set of well
according to174.
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Figure 5.4. Uptake of [14C]-2-DOG by isolated P. falciparum trophozoites at increasing
concentrations of hit compounds. Distribution ratios (i.e., the ratio of intracellular
concentration of radiolabel relative to the extracellular concentration) were calculated as
described previously43. IC50 values were calculated using non-linear regression analysis and are
tabulated in Table 1. Uptake data are expressed as means ±SEM. Chemical structures of the
compounds tested are shown for comparison.
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Figure 5.5. Copies of transcript per ng of cDNA for each glucose transporter SLC2A family
member in HEK293-FLIP cells overexpressing (a) hGLUT1, (b) hGLUT2, (c) hGLUT3 and (d)
hGLUT4 in comparison to HEK293 wild-type and/or HEK293 wild type cells treated with siRNA
targeting hSLC2A1 (hGLUT1 kd).
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Figure 5.6. Specificity of hit compounds for PfHT over human orthologues. (a) Uptake of 3H-2DOG by HEK293 cells overexpressing hGLUTs 1-4 in the presence of hit compounds at their IC50 for PfHT (Table 1). (b) Uptake of [3H]-2-DOG by HEK293 cells overexpressing PfHT or hGLUTs 1-4
at increasing concentrations of compound MMV009085. Uptake data are expressed as means
±SEM. IC50 values were calculated using non-linear regression analysis.

115

5.9 Tables
Table 5.1. Comparison of hit IC50 values for different assays. IC50 for PfHT in parasites were
determined from dose-response curves shown in Fig. 5.4. IC50 values for inhibition of growth of
P. falciparum strain 3D7 intraerythrocytic forms by each compound are also tabulated.
Compound ID #

IC50 3D7 in vitro (μM)

IC50 PfHT in parasites (μM)

MMV020548

0.114

21.3

MMV665941

0.026

13.3

MMV009085

0.987

1.8

MMV000326

0.344

139

MMV665879

0.390

6.6

MMV665898

0.487

6.2

Table 5.2. Human glucose transporter primers for qPCR.

GLUT1
GLUT2
GLUT3
GLUT4
GLUT5
GLUT6
GLUT7
GLUT8
GLUT9
GLUT10
GLUT11
GLUT12

Forward primer :
AACTCTTCAGCCAGGGTCCAC
TTTCAGGCCTGGTTCCTATG
ACTTTGACGGACAAGGGAAATG
CATGCTGGTCAACAATGTCC
GTCGGCCCCTTGGTGAATAA
GGCTGCTCATGTCTGAGGTC
TGCAGGCATCTCCTACAGC
CCATCTTTGAAGAGGCCAAG
TGGCAAAGATCCCATACGTC
GCTGTCCTGCAATCCCTCAG
GGAGTCAATGCAGGTGTGAG
TGCTGGATTAAGCCACACTG

Reverse primer :
CACAGTGAAGATGATGAAGAC
GATGGCCAGCTGATGAAAAG
ACCAGTGACAGCCAACAGG
CCAATGAGGAATCGTCCAAG
AATGATGTGGCGACTCTGCT
GATGGCCGCGAAGAAGAAGAA
ACGAAAACCTCGGTCATTGTTC
ATGACCACACCTGACAAGACC
AGGTGCTCAATGACCAAACC
GTCCGGCCTCGCATGTTATC
CCAGAGCCGTAAAGATGGCTG
TGGCTAAGGACAGCCATTTC
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Amplicon size (bp)
140
86
180
105
110
161
96
145
85
173
112
83

Chapter 6 - Conclusions
With recognition of the fundamental importance of facilitative glucose transport in both health
and disease together with major remaining gaps in understanding the molecular mechanisms
responsible for mediating and regulating this process, initial effort was directed toward
overcoming the most significant barrier to the study of integral membrane proteins. The first
priority addressed was the development of a robust system for overexpression, purification and
functional reconstitution of GLUT4 in artificial membranes. This work, described in detail in
chapter 2 of this dissertation, has been successful in generating a reliable means to obtain
milligram quantities of nearly homogeneous protein. It is notable that the newly developed
inducible mammalian cell lines in suspension culture produced are capable of producing over
1.5 mg of GLUT4 protein per liter of culture media. In the process of developing these novel
methods, several important insights regarding transporter stability and influences on maximal
glucose transport rates were discovered. The application of FSEC to GLUT4 allowed the creation
of a multi-step process to identify cell lines with high expression, to identify detergents that are
harsh enough to solubilize the transporter from its membrane environment but still mild
enough to keep its tertiary structure intact and to purify solubilized proteins. Of note, our twostep purification protocol is capable of yielding protein with >95% purity, allowing study of
GLUT4 with a variety of established and newly emerging biophysical techniques such as smFRET
and EPR DEER spectroscopy.
With this established purification framework in hand, tremendous opportunity remains for the
extension of this approach to the investigation of other SLC2A family members. Ongoing
modification and optimization of the procedures outlined in Chapter 2 are being used for the
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expression and purification of several additional GLUT isoforms and other difficult-to-purify
mammalian membrane proteins. This stream-lined approach is significantly reducing the time
from DNA sequence to purified protein from greater than 2 years to less than 4 months.
The development of protocols for the reconstitution of GLUT4 in different membrane mimetics
that significantly stabilize the protein compared to detergent micelles is also contributing to
ongoing efforts to investigate structure and molecular dynamics. Building on our previous
results, reconstituted GLUT4 and GLUT3 protein in liposomes were used to determine the
influence of various phospholipids, found in mammalian PMs, on the activity of these
transporters. We determined that anionic phospholipids are required for GLUT3 and GLUT4
activity while conical lipids increase transporter activity several fold in the presence of anionic
lipids. We further investigated these effects to decipher the mechanism by which these lipids
influence transporter function. Both types of lipids manipulate transporter interconversion
between inward and outward facing conformations in different ways. According to our
proposed model, anionic phospholipids bind to a specific anionic phospholipid binding site on
the transporters, forming a salt bridge between the negative charge on the phosphate
headgroup and a cationic amino acid on the transporter, thereby allowing the transporter to
interconvert between conformations. Increasing concentrations of anionic lipids lead to an
increase in the fraction of active transporters. Conical lipids, on the other hand, change the
biophysical properties of the lipid membrane by introducing lipid packing defects, decreasing
lateral pressure at the lipid-water interface and increasing curvature frustration. These changes
lead to a dose-dependent increase in the interconversion rate of the transporters, caused by a
destabilization of the inward and outward open states. These groundbreaking discoveries
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prompted the question as to whether our model of transporter activation is applicable to other
members of the GLUT family or even the entire superfamily of SLCs. Studies are currently
ongoing to test the lipid dependence of several members of the class 1 and class 2 GLUTs. The
differences and similarities of lipid effects on activity between different transporters will have a
significant impact in understanding their role on health and disease.
Based on these successes, I expanded the focus of glucose transport as a drug target for several
diseases. The malarial glucose transporter PfHT was chosen for its significance in malarial
metabolism. We identified PfHT as a target for the clinically used HIV protease inhibitor
lopinavir. This drug was reported to cause a reduction of malaria infection in children by over
40%45 and was known to decrease viability of malarial parasites in different life stages but its
mechanism of action was unknown46–50. Identification of PfHT as a target of lopinavir with
potent effects in vitro, in vivo, and in patients stresses the importance of the malarial glucose
transporter as an attractive drug target. Although, lopinavir is already approved for clinical use,
due to its relative high IC50 for PfHT and higher selectivity for other human glucose
transporters170, further work is required to identify inhibitors with improved potency and
selectivity. High throughput screens of large, chemically diverse compound libraries against
molecular targets are commonly used for inhibitor identification. We developed an assay with
high throughput capability that can identify PfHT inhibitors with high accuracy (Z’ factor > 0.8)
and high selectivity over human orthologues. Additionally, this assay can be used to identify
isoform selective inhibitors of human GLUTs as potential therapeutics in cancer therapy. It uses
a genetically encoded glucose sensor that changes its fluorescence signal with intracellular
glucose concentration. Proof of concept screening of a small, targeted library revealed several
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verified hits and signified several advantages of this assay compared to traditional radiolabeled
uptake assays or cell-death based assays: As the screening assay doesn’t involve radiolabeled
chemicals while still directly measuring transporter function in comparison to cell death, it
doesn’t require expensive radiochemicals, avoids safety precautions and special waste removal
while providing high accuracy and low false positive rates.

Chapter 7 - Future directions

7.1 Deciphering the effect of lipids and cholesterol on glucose transporter function
I believe that we only discovered the tip of the iceberg in our understanding of the impact of
the PM composition on the activity of mammalian solute carriers. Open questions revolve
around the effect of other molecules within the mammalian PM on transporter activity,
especially signaling lipids and cholesterol. Although, signaling lipids like phosphorylated forms
of PI (PIPs) or sphingosines are present at very low concentrations in the PM, they have a
substantial effect on the activity and regulation of ion channels181,182 but their effect on
transporter proteins remains elusive. The sterol cholesterol is a major component of
mammalian PMs, constituting about 20-50% of eukaryotic membranes while being universally
absent in membranes of prokaryotes20,183. It has been shown to affect the structure, activity
and regulation of several classes of integral membrane proteins like ion channels 184,185 or Gprotein coupled receptors186–188, either through direct interaction with the protein 187,189 or
through changes of the membrane biophysical properties 186. The effect of cholesterol is
controversially discussed in the context of GLUT function in humans. Studies, highlighting the
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increased activity of glucose transporters in cells after cholesterol removal using methyl-betacyclodextrin (MBCD)190,191, are contradicted by data supporting decreased glucose transporter
activity in multiple cell lines as a result of MBCD treatment or by the cholesterol lowering
effects of statins192. Moreover, it remains unclear if the effect of cholesterol on the transporter
is caused through a change in translocation or affecting transporter turnover, either through
direct interaction with the protein or by affecting lipid bilayer properties. The purification and
functional reconstitution system we established (described in Chapters 2 and 3) allows us to
investigate the effect of each membrane component on the activity of individual GLUT
isoforms. It uniquely positions us to systematically answer these and other questions which was
not previously possible in a cellular system. We are able to measure kinetic parameters and
thereby determine cholesterol’s effect on the turnover number of different GLUT isoforms.
Furthermore, a clear distinction can be made between a direct binding effect and an effect on
the biophysical properties of the membrane by using the complete enantiomer of naturally
occurring cholesterol which retains its effect on the lipid bilayer but cannot occupy a protein
binding site of the natural enantiomer.
In our previous studies, the main focus was on the effect of the phospholipid headgroups on
glucose transporter function. Interestingly, not only the headgroup but also differences in lipid
acyl chain length and saturation have been linked to changes in glucose transport in patients
with diabetes115. Deciphering their direct contributions and mechanism of action on glucose
transporter activity will provide key indications for novel ways of improving the treatment of
diabetes patients through dietary or pharmacological intervention.
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7.2 Refining the mechanism of lipid effects on GLUT activity
In Chapter 3, we proposed a model for GLUT activation through anionic and conical lipids.
Having already obtained a significant amount of data that supports this hypothesis, further
investigation of specifically the anionic phospholipid binding site and the differential effect of
anionic and conical lipids on transport rates and occupation of protein conformations will yield
valuable information to refine our model. I propose several complimentary techniques to
determine the location and the number of anionic phospholipid binding sites as well as the
amino acids involved. Although, membrane protein crystallography is still challenging and
success is not guaranteed, co-crystallization of GLUT3 with anionic lipids presents a worthwhile
approach that could a yield high-resolution structure of the protein-lipid complex. This is
especially true as the crystallization conditions for GLUT3 are already known (PDB accession
number 56C5) and the protein which was used for structure determination showed headgroup
dependent activation through anionic phospholipids (Chapter 3, Fig. 3.2d). Alternatively, MD
simulations have previously been used to determine lipid binding sites and also the effect of
lipid binding on transporter dynamics 133. In order to fully understand the differences between
anionic and conical lipids on the mechanism of transporter activation, it is necessary to depart
from ensemble methods and employ single molecule techniques. We proposed that anionic
lipids alter the fraction of active transporters in a dose-dependent manner while conical lipids
increase the transport rate of every transporter molecule. When the turnover number kcat is
determined as readout for interconversion rate for both lipid classes using ensemble methods,
both mechanisms yield the same phenotype and are indistinguishable (Chapter 3, Fig. 3.5).
However, by determining the interconversion rate of individual transporters via single molecule
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techniques, I expect to observe a change in the fraction of active transporters, interconverting
at a similar rate with increasing concentration of anionic phospholipids (Fig. 7.1a). Conical
lipids, on the other hand, would increase the interconversion rate for the entire transporter
population in a dose-dependent manner (Fig. 7.1b). An ideally suited technique to test this
hypothesis is smFRET. Here, two artificially introduced cysteine residues on the protein are
labeled with fluorophores that transfer energy from the donor to the acceptor molecule
through nonradiative dipole-dipole coupling upon excitation of the donor. The efficiency of this
transfer is inversely proportional to the sixth power of the distance between donor and
acceptor, making smFRET extremely sensitive to small changes in distance 193. Labeled proteins
are immobilized on a glass slide and changes in fluorescence intensity are recorded using
ultrasensitive CCD or CMOS cameras via TIRF microscopy. Positions for fluorophore labeling on
the GLUT transporter need to be carefully chosen to maximize the distance change between
fluorophores in different conformations and to ensure high exposure of cysteine residues for
covalent labeling with water soluble fluorophores to maximize labeling efficiency. We have
already generated a cysteine free mutant of GLUT4 where all native cysteines were replace with
serine residues. The cysteine free mutant showed similar activity when expressed in HEK293
cells compared to the native transporter. Using a protocol, developed previously (Chapter 2),
we successfully reconstituted several versions of double-labeled GLUT4 protein into lipid
nanodiscs and adhered them to a streptavidin coated glass slide via biotinylated lipids
headgroups in lipid nanodiscs. Currently, efforts are ongoing to identify cysteine pairs whose
distances, measured by smFRET, correspond to inward and outward facing conformations of
GLUT4. FRET intensities will be correlated with conformational states using transporters locked
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into single conformations via point mutations or small molecule inhibitors. The system
described here offers several advantages including stabilization of a soluble, highly
homogenous membrane protein population while embedding the protein in a near native lipid
environment which can be precisely manipulated to determine the effect of various lipids on
transporter dynamics and distribution of states.

7.3 Identification and development of potent and selective inhibitors of PfHT
The herein described high throughput assay was successfully tested on a small, directed
compound library. The next steps involve screening large, chemically diverse library and further
assay optimization. Increasing the throughput and sensitivity will make large screens more cost
effective. Currently, the assay is optimized for a 96-well format. Increasing the number of wells
per plate decreases the required amount of test compounds, cells and ultimately cost, while
increasing throughput. Additionally, alternative detection methods like fluorescence lifetime
can be explored to increase the sensitivity177,178 and thereby the Z’ factor.
Based on our previous results, I expect that a large, chemically unbiased screen will yield
several diverse molecules with high potency against PfHT. These primary hits will be verified
through uptake assays of radiolabeled substrate and structurally similar compounds of verified
hits will be evaluated to identify a common backbone. Structure activity relationship (SAR)
studies will use this information to modify the structure of verified hits by inserting new
chemical groups into the biomedical compound and test the modifications for their biological
effects. The resulting lead compounds should have high potency in vitro and in animal models
(IC50 in the nanomolar range), good drug metabolism and pharmacokinetic (DMPK)
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characteristics, show more than 10-fold higher selectivity for PfHT over its human orthologues,
demonstrate good oral bioavailability in rodents and display no acute toxicity in in vivo efficacy
studies176.
The ultimate outcome of this screen, inhibitors with high selectivity for specific glucose
transporters, together with currently emerging crystal structures of these transporters will help
determine the structural requirements for designing highly selective, isoform or orthologue
specific inhibitors, thereby minimizing off-target effects.
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7.4 Figures

Figure 7.1. Prediction of the interconversion rate of glucose transporters measured via
smFRET. (a) Anionic phospholipid dependent change in the interconversion rate of GLUT4
protein in nanodiscs. (b) Conical lipid dependent change in the interconversion rate of GLUT4
protein in nanodiscs.
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